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CHAPTER I 
 
INTRODUCTION 
 
Organization of the Human Antibody Germline Locus 
 
Antibodies are antigen receptors expressed by B cells and are critical to the 
eradication of pathogenic infection and establishment of immunological memory. The 
antibody protein consists of two identical heavy chains associated with two identical light 
chains. The antibody genes that encode heavy and light chains are located in three primary 
locations in the human genome: heavy chain genes (IGH) are located on chromosome 14, 
light chain kappa genes (IGK) are located on chromosome 2, and light chain lambda genes 
(IGL) are located on chromosome 22 (Brochet et al., 2008). Each of these loci consists of 
multiple variable (V) and joining (J) gene segments, and the IGH locus also contains several 
diversity (D) gene segments. Sequencing of the human IGH locus revealed 44 functional V 
Figure 1. Organization of the human heavy chain locus. All functional heavy chain variable genes are shown 
(green) as well as all ORF variable genes (red). Variable genes that are suspected to reside in regions of 
insertion (filled circles) or deletion (open circles) polymorphisms are indicated. Image adapted from IMGT.org. 
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genes (and 85 pseudogenes), 27 D genes (23 functional), and nine J genes (6 functional) 
(Matsuda et al., 1998). Further sequencing has resulted in the identification of 11 additional 
functional V gene segments that were not present in the original reference genome (Lefranc 
et al., 2009). A simplified diagram of the IGH locus is shown in Figure 1. 
The human variable genes (and, at the IGH locus, the diversity genes) can be 
phylogenetically grouped into families based on sequence similarity. Heavy chain variable 
genes are organized into seven families and homology within gene families is typically 
above 80%. Sequence homology between heavy chain variable genes belonging to different 
families is less than 70%. The 23 functional human diversity genes are also organized into 
seven families. In the germline locus, the diversity genes are uniquely positioned in four 
tandemly oriented groups (Siebenlist et al., 1981; Corbett, 1997), and are located 
approximately 8kb upstream of Cµ, the nearest constant region gene. The unique 
positioning of diversity genes in regularly spaced 9kb clusters suggests that the locus may 
have been created by a series of duplications (Siebenlist et al., 1981; Ichihara et al., 1988). 
The standard IMGT nomenclature for human V and D genes follows the following pattern: 
the chain and gene description (IGHV for variable genes, IGHD for germline genes), the 
family, the gene number (determined by position in the germline locus), and the allele. The 
gene number is separated from the family with a hyphen and the allele is separated from the 
gene number with an asterisk. Thus, an example variable gene nomenclature appears as: 
IGHV1-2*03. 
 
V(D)J Recombination 
 
Since the discovery that RAG-mediated recombination of variable, diversity and 
joining genes generates virtually unlimited sequence diversity in the antibody repertoire 
(Brack et al., 1978; Alt and Baltimore, 1982; Tonegawa, 1983; Schatz et al., 1989; Oettinger 
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et al., 1990), much progress has been made in determining the genetic and mechanistic 
elements that participate in the antibody recombination process. It is generally understood 
that recombination signal sequences (RSS), which flank V, D and J genes and are 
composed of conserved AT-rich heptamer and nonamer sequences separated by spacers of 
either 12 or 23 nucleotides, are recognized and bound by recombination activating gene 
(RAG1 and RAG2) proteins at the initiation of the recombination process (Hesse et al., 
1989; Alt et al., 1992). RAG binding is highly dependent on the heptamer and nonamer 
sequences, and alterations to either sequence results in decreased RAG binding (Cuomo et 
al., 1996; Difilippantonio et al., 1996; Nadel et al., 1998). The length of the spacer sequence 
is critical to recombination, and there is evidence of sequence conservation within the 
spacer region (Ramsden et al., 1994; Lee et al., 2003; Montalbano et al., 2003).  
Recombination typically occurs only between RSS elements of different spacer 
lengths, in a model commonly referred to as the 12/23 rule of recombination (Ramsden et 
al., 1996; Steen et al., 1996; van Gent et al., 1996; Schatz, 2004). After binding to one 12-bp 
RSS and one 23-bp RSS, the RAG complex induces single-strand DNA nicks between the 
Figure 2. V(D)J recombination at the human heavy chain locus. Recombination between VH (blue), DH 
(red) and JH (green) genes is mediated by 12bp RSSs (open arrows) and 23bp RSSs (filled arrows). The 
final recombinant includes N-addition at the V-D and D-J junctions (yellow). 
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coding sequence and the heptamer of each RSS, resulting in hairpin formation on each of 
the coding ends and a blunt double-stranded break on each signal end (Roth et al., 1992; 
Schlissel et al., 1993; McBlane et al., 1995; Sadofsky, 2001). The hairpins are opened, 
nucleotides may be added to or removed from the coding ends, and the double strand 
breaks at the coding ends are joined into a single coding strand (Lewis, 1994; Mahajan et 
al., 1999; Shockett and Schatz, 1999; Walker et al., 2001; Mansilla-Soto and Cortes, 2003; 
Roth, 2003).  
In antibody heavy chain genes, diversity genes are flanked by 12-bp RSSs on either 
side, while variable and joining genes are flanked by 23-bp RSSs (Early et al., 1980; 
Kurosawa and Tonegawa, 1982). Recombination of the light chain is the result of a single 
VL-JL recombination; heavy chain recombination (Figure 2) occurs in step-wise fashion, with 
D-JH recombination preceding VH-D recombination (Alt et al., 1987; Schatz et al., 1992). 
 
Somatic Hypermutation 
 
Establishment of a diverse primary (or naïve) antibody repertoire is a result of RAG-
mediated recombination. Diversification of the secondary antibody repertoire, which arises in 
response to antigenic stimulus, is accomplished primarily through somatic hypermutation 
(SHM) (Brenner and Milstein, 1966; Kelsoe, 1994). Naïve, antigen inexperienced B cells 
undergo the SHM process upon recognition of an infectious agent. It is through the SHM 
process, which occurs primarily in secondary lymphoid tissue, that they mutate the variable 
region of their antibody genes (MacLennan et al., 1992; Li et al., 2004). Many of these 
mutations have no effect on antigen recognition and many have deleterious effects on either 
antigen recognition or proper folding of the antibody protein, however, some mutations 
produce antibodies with improved affinity for the target pathogenic epitope (Casali et al., 
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2006). Thus, the SHM process provides a basis for the positive selection of high affinity 
antibodies that are characteristic of a mature immune response (MacLennan, 1994).  
Many components of the SHM machinery are known, but the complete process and 
the mechanisms by which it is targeted specifically to the immunoglobulin loci are still poorly 
understood. SHM introduces point mutations at a frequency of approximately 10-3 mutations 
per base pair, which is 106-fold higher than the rate of spontaneous mutation in other genes 
(Rajewsky et al., 1987). Mutations begin approximately 150-bp downstream of the 
transcription start site and the mutation frequency decreases exponentially with increasing 
distance from the transcription start site (Rada and Milstein, 2001). Activation-induced 
cytidine deaminase (AID) is required for SHM and initiates the SHM process by the 
deamination of cytosine nucleotides, which results in the conversion of cytosine to uracil 
(Muramatsu et al., 1999; 2000). Deamination thus produces a uracil-guanine mismatch, and 
several possible processes result in the error-prone repair of the mismatch. The precise 
mechanism(s) responsible for error-prone repair during SHM are not known, although 
several DNA repair mechanisms have been shown to be critical to the SHM process, 
including base excision repair and mismatch repair (Phung et al., 1998; Rada et al., 1998; 
Wiesendanger et al., 2000; Di Noia and Neuberger, 2002; Zheng et al., 2005). 
Antibody complementarity determining regions (CDRs, also referred to as 
hypervariable regions) are the primary region of antigen recognition and are preferentially 
targeted for affinity maturation by the SHM machinery, making them the most variable 
regions of the antibody gene (Capra and Kehoe, 1975; Kabat et al., 1992). There are 
several structural and genetic reasons for the preferential targeting of CDRs by SHM. 
Genetically, SHM is known to preferentially target the WRCY hotspot motif (or its reverse 
complement, RGYW) (Dörner et al., 1998), and the frequency of these hotspots is increased 
in CDRs (Wagner et al., 1995; Shapiro and Wysocki, 2002; Pham et al., 2003). Further, 
codon usage is biased in CDRs toward codons that are easily mutable, enhancing the 
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likelihood that a nucleotide substitution induced by SHM results in an amino acid change 
(Motoyama et al., 1991; Wagner et al., 1995; Kepler, 1997). Structurally, the CDRs are 
largely loop-based, which make them sufficiently flexible to incorporate the substitutions and 
short indels introduced by SHM without compromising structural integrity. Framework 
regions (FRs), by contrast, are highly structured and less able to accommodate somatic 
mutations (Celada and Seiden, 1996). 
 
Secondary Mechanisms of Affinity Maturation 
 
V(DD)J and direct VH-JH recombination 
Direct VH-JH joining and V(DD)J recombination (also referred to as D-D fusion) are in 
direct violation of the 12/23 rule, but such recombination events have been demonstrated in 
both in vitro and in vivo systems (Sanz, 1991; Kiyoi et al., 1992; Raaphorst et al., 1997; 
Koralov et al., 2005; 2006; Watson et al., 2006). Even in model systems designed to induce 
such recombination events, however, non-12/23 recombinations are much less efficient than 
recombinations that adhere to the 12/23 rule (Akira et al., 1987; Hesse et al., 1989; 
Akamatsu et al., 1994). 
V(DD)J recombinants are the result of an aberrant recombination process by which 
two or more diversity genes are joined into a single recombinant. The joining of two diversity 
genes, which are flanked on both sides by 12-bp RSSs, can only be accomplished in clear 
violation of the 12/23 rule, but such recombination events have been seen both in vivo and 
in vitro (Sanz, 1991; Kiyoi et al., 1992; Raaphorst et al., 1997; Watson et al., 2006). V(DD)J 
recombinations have been estimated to occur in as many as 5-11% of all recombinations 
(Sanz, 1991; Kiyoi et al., 1992; Raaphorst et al., 1997), but the true frequency of V(DD)J 
recombinations is difficult to determine. Identification of V(DD)J recombinants relies on the 
accurate detection of two diversity genes within a single recombinant, but N-addition 
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mimicry of diversity gene segments, which is genetically indistinguishable from true V(DD)J 
recombination, likely inflates current estimates of V(DD)J recombination (Watson et al., 
2006). 
 
VH replacement and receptor revision 
VH replacement is a process by which a secondary VH-V(D)J recombination can 
occur, resulting in replacement of the variable gene while preserving the original D-JH 
recombination (Nemazee, 2006). VH replacement differs from receptor editing, which is the 
process of secondary rearrangement in light chains. Receptor editing results in an entirely 
new VL-JL recombination through the recombination of a VL gene segment upstream of the 
original recombination with a JL gene segment downstream of the original recombination 
(Papavasiliou et al., 1997; Retter and Nemazee, 1998). Thus, receptor editing proceeds 
without violating the 12/23 rule. VH replacement utilizes a cryptic RSS (cRSS) found near the 
3ʹ′ end of most human variable genes (Radic and Zouali, 1996), and this cRSS is used to 
recombine with the normal RSS at the 3ʹ′ end of the invading variable gene. The cRSS 
contains a heptamer sequence, but lacks an identifiable nonamer or spacer sequence, and 
recombination with the cRSS is inefficient, much like other forms of non-12/23 
recombination (Koralov et al., 2006; Lutz et al., 2006). 
VH replacement was observed first in transformed murine pre-B cells (Kleinfield et 
al., 1986; Reth et al., 1986), with subsequent studies identifying VH replacement in vivo (Taki 
et al., 1993; Chen et al., 1995). In the most informative work done on VH replacement in the 
human repertoire, a genetic fingerprint of VH replacement was identified in the human 
peripheral blood repertoire (Zhang et al., 2003). Identification of VH replacement events in 
the peripheral repertoire relies on detection of short pentameric sequences that are located 
between the cRSS and the 3ʹ′ end of variable genes. These pentamers remain even after VH 
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replacement, providing an identifiable remnant of the replaced variable gene. Short 
pentameric sequences are easily mimicked through random N-addition, making reliable 
detection of VH replacement difficult. As such, estimates of VH recombination frequency in 
the peripheral blood repertoire have varied widely, from 5% to 22% of the total repertoire 
(Zhang et al., 2003; Koralov et al., 2006; Watson et al., 2006). 
 
Somatic hypermutation-associated insertions and deletions 
Although the somatic hypermutation process typically results in single nucleotide 
substitutions, deletion of germline nucleic acids or insertion of non-germline nucleic acids 
does occur in association with somatic hypermutation (Goossens et al., 1998; Wilson et al., 
1998a; Bemark and Neuberger, 2003). These insertions and deletions are rare, with somatic 
hypermutation-associated (SHA) insertions or deletions estimated to be present in 1.3 to 
6.5% of circulating B cells (Goossens et al., 1998; Wilson et al., 1998a; Bemark and 
Neuberger, 2003). Short SHA indels are much more common than long SHA indels, with 
most insertions and deletions being 1-2 codons in length (Goossens et al., 1998; Wilson et 
al., 1998a; Bemark and Neuberger, 2003). Although infrequent, SHA insertion and deletion 
events add substantially to the diversity of the human antibody repertoire (Wilson et al., 
1998b; de Wildt et al., 1999; Reason and Zhou, 2006). 
SHA insertions and deletions also have been shown to play a critical role in the 
antibody response against viral and bacterial pathogens, including HIV, influenza, and 
Streptococcus pneumoniae (Zhou et al., 2004; Walker et al., 2009; Wu et al., 2010a; Krause 
et al., 2011; Pejchal et al., 2011; Walker et al., 2011). Of particular interest, structural 
analysis of an SHA insertion in the anti-influenza antibody 2D1 identified a substantial 
structural alteration induced by the insertion (Krause et al., 2011). This insertion, although 
located in a framework region, caused a large conformational change in a CDR and allowed 
antibody-antigen interactions that were sterically hindered without the insertion-induced 
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conformational change. In addition to 2D1, the extremely broad and potently neutralizing 
HIV antibody VRC01 contained a six nucleotide deletion in the CDR1 of the light chain 
(CDR-L1) (Wu et al., 2010a). This SHA deletion shortened the CDR-L1 loop, thereby 
removing potential clashes with loop D of the HIV envelope protein and allowing direct 
interaction between the HIV antigen and the CDR-L2 loop of VRC01 (Zhou et al., 2010). 
 
Affinity maturation and antigen contact by antibody framework regions 
While much affinity maturation effort is expended on the CDRs, there are other 
regions that are important to antigen recognition. T cell receptors (TCRs) contain a fourth 
hypervariable region (HV4, sometimes referred to as CDR4), which is highly variable, 
surface exposed, and is involved in superantigen and accessory molecule recognition (Choi 
et al., 1990; Garcia et al., 1996; Li et al., 1998).  
Emerging evidence suggests that an HV4-like region may exist in antibodies as well 
as TCRs. Recent crystallographic work on the anti-influenza antibody CR6261 has shown 
that the HV4-like region of FR3 was somatically mutated (Throsby et al., 2008) and directly 
contributed to antigen binding (Ekiert et al., 2009). The anti-influenza antibody 2D1 contains 
a three codon insertion in a HV4-like region of FR3 which, while not directly involved in 
antigen recognition, causes a critical conformational shift in nearby CDRs that is required for 
antigen recognition (Krause et al., 2011). A unique example of HV4-like contribution to 
antigen recognition is the anti-HIV antibody 21c (Diskin et al., 2010). 21c binds to the HIV 
co-receptor binding pocket, which is only exposed following binding of CD4, the primary host 
receptor. Interestingly, while the majority of the binding surface of 21c is in contact with the 
HIV envelope protein, the HV4-like region of 21c binds to CD4, forming a cross-protein 
epitope. In addition to 21c, the broadly neutralizing anti-HIV antibody VRC03 contains a 
surprisingly long seven codon insertion in the HV4-like region of FR3 (Wu et al., 2010a). 
Finally, the HV4-like FR3 region of antibody heavy chains of the VH3 family has been shown 
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to interact with Staphylococcal protein A, a known superantigen (Potter et al., 1996), 
mimicking the superantigen-binding activity of the HV4 region in TCRs. While the HV4-like 
regions that have been identified to date are not somatically mutated to the same extent as 
antibody CDRs, the ability of this HV4-like region to tolerate a substantial number of somatic 
mutations and genetic insertions suggests the existence of a somewhat flexible region that 
has an under-appreciated ability to accommodate affinity maturation modifications. 
 
Human Immunodeficiency Virus 
 
Structure, function and diversification of HIV Env 
 Human Immunodeficiency Virus Type 1 (HIV-1), a member of the Retroviridae family, 
Figure 3. Structure of the HIV virion particle. Image adapted from AIDSreagents.org. 
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is an enveloped virus containing a positive-strand RNA genome (Figure 3). During 
replication, the RNA genome is converted to double-stranded DNA by the highly error prone 
reverse transcriptase enzyme, which generates point mutations and intergenomic 
recombination and creates massive diversity in the viral envelope (Env) protein as well as 
other viral proteins. Based on genome diversity, HIV isolates can be classified into three 
groups: M (Major), N (Non-M, Non-O) and (Outlier). Group M, which is the most prevalent, is 
further classified into subtypes or clades (A-D, F-H, J and K). Clade B is the most frequently 
found circulating clade in the United States, while clade C is the most common subtype in 
India, China and Sub-Saharan Africa. In addition to the major clades, circulating 
recombinant forms of HIV exist and display genetic characteristics of several clades, 
presumably formed through intergenomic recombination. 
 The functional spike on the surface of the virion is the Env glycoprotein. The Env 
glycoprotein complex is originally produced as a single-chain glycoprotein precursor, gp160, 
which is cleaved by a cellular protease. Cleavage of gp160 results in the cell-surface 
attachment protein gp120 and the membrane-spanning protein gp41. The gp160 cleavage 
products are noncovalently linked and assemble into a trimer of gp120-gp41 heterodimers 
that is expressed on the virion surface (Kowalski et al., 1987; Lu et al., 1995). Gp120 is 
heavily glycosylated, with nearly half the total mass being the result of N-linked glycans 
(Poignard et al., 2001). It is composed of five variable regions (V1-V5) interspersed with five 
constant regions (C1-C5) (Starcich et al., 1986).  
The principle function of the glycoprotein spike is to facilitate cell entry by binding to 
the primary cell-surface receptor, CD4, and one of the two co-receptors, CCR5 and CXCR4. 
Binding to the receptor and co-receptor is accomplished by gp120, and fusion of the viral 
and cell membranes is mediated by gp41 (Zwick et al., 2004b). Gp41 is relatively well 
conserved, but most of its surface appears to be shielded from antibody recognition before 
attachment and fusion (Weiss, 2003). 
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Evasion of the humoral immune response  
 The enormous variability of HIV is an effective mechanism for evading neutralizing 
antibody. The sequence variation in one isolate from a single HIV-infected individual 
sampled a few years after infection is greater than the global variation of an influenza 
epidemic strain during a flu season (Korber et al., 2001). In HIV Env, sequence variability is 
concentrated in the variable loops (V1–V5), which appear to be a major target for 
neutralizing antibody responses. Escape from these responses is readily achieved by 
mutations in the loops that have only minor consequences for viral fitness. Longitudinal 
studies in humans show that a neutralizing antibody response to the dominant virus does 
develop but, once a threshold is reached, an escape variant is selected (Richman et al., 
2003; Wei et al., 2003). In turn, an antibody response to this variant develops over time that 
results in the selection of a new escape variant and further repetition of the process. 
Numerous monoclonal antibodies (mAbs) to Env have been isolated from humans, but only 
a few of these can effectively neutralize most strains of the virus (Burton et al., 1994; Binley 
et al., 2004; Zolla-Pazner et al., 2004; Burton et al., 2005a; Cardoso et al., 2005; Haynes 
and Montefiori, 2006; Walker et al., 2009; Wu et al., 2010a; Walker et al., 2011). This 
highlights one of the central features of the humoral immune response against HIV-1: Most 
of the anti-Env antibodies generated during natural infection are directed to regions of gp120 
or gp41 that are not exposed on the mature functional virus spike. This may arise because 
gp120 readily dissociates from gp41 and because certain epitopes on monomeric forms of 
gp120 and exposed regions of gp41 are highly immunogenic (Haynes and Montefiori, 2006; 
Pantophlet and Burton, 2006). This results in a large proportion of antibodies that can be 
detected by gp120 or gp140 binding assays, but are unable to bind the native virus spike 
and neutralize the virus. However, sera from some HIV-1-infected subjects are able to 
potently neutralize diverse isolates of HIV-1 (Dhillon et al., 2007; Li et al., 2007; Binley et al., 
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2008; Sather et al., 2009; Simek et al., 2009), which demonstrates that there are vulnerable 
regions on the functional Env trimer. Antibodies that can recognize many different variants 
of HIV, so-called broadly neutralizing antibodies (bnAbs), are thought to evolve slowly and 
only in some individuals. It is precisely this type of antibody that one would like to elicit by 
vaccination, and so they have attracted special interest. 
 
Broadly Neutralizing HIV Antibodies 
 
A small but growing number of broadly neutralizing monoclonal antibodies, 
antibodies capable of neutralizing HIV isolates from different clades, have been identified 
(Burton et al., 2004). These mAbs are important in vaccine design but, unexpectedly, 
elucidation of their 3D structures has provided remarkable insight into the adaptability of 
antibodies when challenged by a virus that has developed an extensive repertoire of 
antibody evasion techniques. For nearly a decade, only a small panel of broadly neutralizing 
antibodies had been identified. These antibodies targeted three distinct epitopes, and it was 
long presumed that all neutralizing epitopes had been identified. However, recently 
Figure 4. HCDR3 length and somatic mutation frequency in HIV bnAbs. HCDR3 length and mutation 
frequency are negatively correlated (left panel). HIV bnAbs with long HCDR3s (24AA, or two standard deviations 
above the mean HCDR3 length for the total repertoire) are significantly less mutated than bnAbs with HCDR3s 
shorter than 24AA in length (right panel). 
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described bnAbs revealed a novel neutralizing epitope (Walker et al., 2011), raising the 
tantalizing possibility that there are further undiscovered neutralizing epitopes on the HIV 
Env protein.  
While most HIV-infected individuals mount a neutralizing antibody response to 
autologous virus isolates, only rarely do individuals mount a broadly neutralizing antibody 
response. It is not clear why bnAbs are so rarely generated, but it is possible that antibodies 
able to neutralize diverse HIV isolates require uncommonly found genetic elements to 
facilitate broad neutralization. In fact, the growing panel of broadly neutralizing HIV 
antibodies has revealed the use several unique genetic structural and genetic features to 
exploit the few weaknesses in the HIV glycoprotein. Two of the most commonly found 
unique features are the use of extremely long HCDR3 loops and extensive somatic 
mutation. These two features are 
negatively correlated (Figure 4), 
indicating that either a long HCDR3 or 
extensive somatic mutation is required, 
but typically not both. 
 
CD4 binding site antibodies 
 The antibody b12, which binds to 
an epitope that overlaps the CD4 
binding site (CD4bs) on gp120 (Burton 
et al., 1991; Barbas et al., 1993; Burton 
et al., 1994), has been studied 
extensively with regard to its 
neutralization activity in vitro and in vivo. 
Figure 5. Crystal structure of b12 in complex 
with HIV gp120. b12 binds to the CD4bs using only 
heavy chain residues, and three heavy chain 
residues (Asn31, Tyr53 and Trp100) make up over 
40% of the contact surface. From Zhou et al, 2007. 
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At the time of discovery, b12 was the most broad and potently neutralizing anti-gp120 
antibody. In in vitro neutralization assays involving a panel of 90 viruses, the antibody was 
able to reduce viral infection by 50% for approximately half of the viruses within the test 
panel at an inhibitory concentration (IC50) of less than 20 µg/mL (Binley et al., 2004). In vivo 
studies using macaque models of HIV infection have shown that b12 can also protect 
animals against viral challenge (Parren et al., 2001; Veazey et al., 2003). The most 
prominent features of the b12 combining site are a long (18 amino acid) heavy chain 
complementarity determining region 3 (HCDR3) that extends directly out from the surface of 
the antibody like a finger (Figure 5; from Zhou, 2007) and the exclusive use of heavy chain 
residues in the binding interaction (Burton et al., 2005b; Zhou et al., 2007). Computer 
docking and mutagenesis studies on gp120 and b12 have been used to argue that the 
finger-like HCDR3 is able to reach into the recessed CD4 binding site of gp120 (Saphire et 
al., 2001; Pantophlet and Ollmann Saphire, 2003; Zwick et al., 2003). 
 After identification of a panel of HIV-infected individuals whose serum was broadly 
neutralized and focused on the CD4bs, a structure-guided technique was used to engineer 
gp120 by resurfacing the molecule to alter antigenic surfaces while preserving the CD4bs 
(Wu et al., 2010a). This resurfaced, stabilized core protein (referred to as RSC3), in 
combination with a null variant which was identical to RSC3 with the exception of a single 
point mutation that eliminated antibody binding to the CD4bs, was able to effectively 
obscure many highly immunogenic non-neutralizing epitopes and allow focusing on the 
CD4bs. By sorting single B cells using RSC3, three bNmAbs were identified (VCR01-03) 
that neutralized over 90% of circulating HIV-1 isolates with an average IC50 of less than 1 
µg/mL. All three VRC antibodies display extensive somatic mutation, with as many as 40% 
of the variable gene amino acids altered from the germline encoded sequence. In addition, 
VRC01 and VRC03, which are clonally related, contain a six nucleotide deletion in the light 
chain CDR2 (Wu et al., 2010a). A high-resolution crystal structure of VRC01 in complex with 
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a core gp120 protein suggests that 
VRC01 optimally approaches the 
CD4bs and requires minimal 
conformational changes in order to 
bind critical contact residues (Zhou 
et al., 2010). It is thought that the 
breadth of VRC01 is due to the 
precise targeting of the antibody to 
the CD4 binding site with little 
interaction with the variable 
surrounding region, however the 
mechanism of neutralization by VRC01 has been shown to be surprisingly distinct from a 
CD4-like interaction (Li et al., 2011). 
 
Glycan-reactive antibodies 
 A dense array of N-linked glycans, collectively referred to as a glycan shield, covers 
much of the surface of gp120 in envelope spikes. The close spacing between carbohydrates 
on gp120, which is unusual for mammalian glycoproteins, is thought to impose 
conformational constraints on these glycans. It has been postulated that this dense and 
relatively rigid presentation of carbohydrates on gp120, stabilized by a network of hydrogen 
bonds, provides the basis for immunological discrimination of these complex glycan 
networks from self glycans by glycan-binding antibodies (Scanlan et al., 2007).  
The bnAb 2G12 recognizes a cluster of α1 → 2-linked mannose residues on the 
distal ends of oligomannose sugars located on the carbohydrate-covered silent face of the 
gp120 outer domain (Trkola et al., 1996; Sanders et al., 2002; Scanlan et al., 2002). The 
crystal structure of 2G12 revealed that the antibody is able to achieve nanomolar binding 
Figure 6. The unique domain-exchanged structure of 
bnAb 2G12. The heavy chain variable region of one 
antigen-binding fragment (VH, cyan) pairs with the light 
chain variable region of the other antigen-binding fragment 
(VL, dark blue). From Pantophlet et al., 2006. 
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affinity to a glycan array due to the unusual 
configuration of the antigen binding fragments 
(Figure 6; from Pantophlet et al., 2006), which form 
a domain-swapped structure – the variable heavy 
chains (VH) from each Fab arm have exchanged 
positions to interact with the light chain (VL) of the 
neighboring antigen binding fragment (Calarese et 
al., 2003). The result is a multivalent platform for 
the binding interaction with carbohydrate, which 
allows the antibody to be uniquely specific for the 
carbohydrate pattern on the surface of gp120 
(Doores et al., 2010). Co-crystallization of 2G12 
with Man9 GlcNAc2 indicates that this multivalent platform allows 2G12 to interact with up to 
four oligomannose sugars simultaneously. Two of these glycans are located, as expected, 
within the conventional antigen binding sites formed by VL and VH, whereas the other two 
are bound within the newly formed secondary binding site formed by the VH/VH interface 
(Calarese et al., 2003). 
In the past several years, there has been an avalanche of potently neutralizing, 
glycan-specific HIV antibodies. Using large-scale microneutralization screening assays, the 
monoclonal antibodies PG9 and PG16 were isolated from a single African donor infected 
with a clade A isolate (Walker et al., 2009). The neutralization profiles of both antibodies 
were measured to be about an order of magnitude greater than those of previously identified 
bNAbs, and the epitope characterization of PG9 and PG16 revealed unique and complex 
specificities (Walker et al., 2009; Pancera et al., 2010). They were found to interact with an 
epitope formed from the conserved region of the V1/V2 and V3 variable loops, to 
preferentially bind functional Env structure targeting a quaternary epitope, and binding was 
Figure 7. Crystal structure of PG16. 
The ax-head shaped HCDR3 (red) 
has unique secondary structure. From 
Pancera et al., 2010. 
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found to be heavily dependent on glycans (Doores and Burton, 2010; Pejchal et al., 2010). 
In addition, PG9 and PG16, which are presumed to be clonally related, encode what are 
among the longest human antigen-specific HCDR3s described to date (Figure 7; from 
Pancera, 2010). 
Following the discovery of PG9 and PG16 and using the same high-throughput 
microneutralization techniques, seventeen new bnAbs were identified from a group of four 
HIV-infected donors that exhibited exceptionally broad and potent neutralization (Pejchal et 
al., 2011). These antibodies, collectively named the PGT antibodies, range from 10-100 
times more potent than any previously described HIV antibody and targeted novel glycan 
epitopes on HIV gp120. It has been speculated that the enhanced potency of the PGT family 
of antibodies may be partially due to their potential ability to cross-link Env trimers on the 
virion surface (Pejchal et al., 2011; Walker et al., 2011). The PGT antibodies can be further 
segregated by genetic and epitope similarities. Four antibodies, PGT141-145, are purported 
to target the same quaternary epitope as PG9 and PG16, are dependent on carbohydrate 
interactions, and encode HCDR3s that are even longer than the exceptionally long HCDR3s 
encoded by PG9 and PG16. Several other members of the PGT family, PGT125-128 and 
PGT130-131, specifically target Man8/9 glycans on gp120 and target an epitope that is 
similar to that of 2G12 (Walker et al., 2011). Of notable importance, several of the PGT 
antibodies are of complementary neutralization breadth, such that a cocktail of PGT 
antibodies provides high potency and extremely broad coverage of HIV isolates (Walker et 
al., 2011). 
 
MPER-specific antibodies 
Although most of the surface of gp41 appears to be occluded from antibody binding 
on Env spikes, a region close to the viral membrane, the membrane-proximal external 
region (MPER), has some accessibility to the neutralizing human antibodies 2F5 and 4E10 
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(Muster et al., 1993; 1994; Purtscher et al., 1994; Stiegler et al., 2001; Zwick et al., 2001). 
Some evidence has emerged that the epitopes of these two antibodies are still accessible, 
and possibly more so, following CD4 binding to gp120 (Binley et al., 2003). Both antibodies 
are thought to recognize linear gp41 epitopes because they bind with relatively high affinity 
to short peptides corresponding to cognate gp41 sequences, and their neutralizing activity 
can be effectively inhibited by such peptides. To date, all attempts to generate neutralizing 
activity by immunization with sequences from these epitopes, either as peptides or 
incorporated into proteins, have been unsuccessful. 
The structure of 2F5, which was described in complex with a 17-mer peptide derived 
from the core linear epitope, revealed the bound peptide epitope in a relatively extended 
conformation (Ofek et al., 2004). Notably, the peptide makes contact with the base of the 22 
amino acid long HCDR3 region but not with much else of this loop. However, mutagenesis 
studies have shown that changes in the apex of the loop can reduce antibody binding to 
peptide and have an even more pronounced adverse effect on neutralization that alterations 
near the base of the loop (Zwick et al., 2004a). These results suggest not only that the long 
loop is required for the creation of the peptide binding site, but also that the tip of the loop 
may be involved in further interactions. A favored current hypothesis is that the loop may 
interact with the viral membrane, and some support for this view is provided by observations 
of enhanced 2F5 binding to MPER peptides when attached to a membrane (Ofek et al., 
2004). 
In contrast to 2F5, a 13-residue peptide containing the core epitope for 4E10 
adopted a helical conformation in complex with antibody (Cardoso et al., 2005). The key 
contact residues mapped to one face of the helix and bound in a highly hydrophobic pocket 
in the 4E10 antibody combining site. As with 2F5, the 4E10 CDRH3 is long and apparently 
not directly involved in peptide binding. The epitope for 4E10 is even closer to the viral 
membrane than that for 2F5, with only a few residues separating the putative C terminus of 
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the epitope and the transmembrane domain. Therefore, the possible interaction of 
tryptophan residues in the CDRH3 with the viral membrane is an attractive hypothesis. This 
notion was supported by enhanced antibody binding to the MPER in the context of a 
membrane (Ofek et al., 2004). A somewhat controversial study highlighted cross-reactivity 
of 2F5 and 4E10 with cardiolipin (Haynes et al., 2005), although this cross-reactivity may 
reflect the hydrophobic nature of the combining sites of these antibodies rather than any 
autoimmune origin. 
Although not currently published, oral presentations have revealed the discovery of 
10e8, another highly potent neutralizing antibody directed against the MPER epitope. It has 
been reported that 10e8 is the broadest antibody known, with the ability to neutralize over 
98% of tested isolates. Further, it is reported to lack the autoreactive qualities of other 
MPER-specific antibodies. 
 
Other neutralizing epitopes 
The third variable loop (V3) of gp120, as its name implies, contains substantial 
sequence divergence between different isolates of HIV. However, the crown of the loop 
contains a relatively conserved sequence motif GPGR or GPGQ that may be important in 
binding to the co-receptor (Hartley et al., 2005). The antibody 447–52D, the most broadly 
neutralizing antibody known to target the V3 loop region, neutralizes a range of isolates 
bearing the GPGR motif, although the neutralization is less broad and potent than other 
bnAbs (Gorny et al., 1992; Binley et al., 2004; Zolla-Pazner et al., 2004). The crystal 
structure of 447–52D in complex with a V3-loop peptide reveals how an antibody can evolve 
to recognize a motif with a conserved core but with a good deal of flanking variation 
(Stanfield et al., 2004). The antibody interacts specifically with the GPGR crown of the V3 
loop, but the flanking sequence is bound by interaction with main-chain atoms. Perhaps in 
response to selection pressure by antibodies akin to 447–52D, many primary viruses appear 
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to have reduced accessibility of the V3 loop to the point where they are no longer 
recognized by such antibodies (Binley et al., 2004). 
 Antibodies which target the HIV co-receptor binding site are typically only able to 
bind in the presence of soluble CD4, indicating that the co-receptor binding pocket is at least 
partially occluded until ligation of the primary receptor (Salzwedel et al., 2000; Xiang et al., 
2002). Antibodies to this CD4-induced (CD4i) site are typically weakly neutralizing and 
display breadth only within clades. Although CD4i antibodies are not potently neutralizing or 
especially broad, they do contain unique features that enable better understanding of HIV-
host interactions. For example, the CD4i antibody 47e contains a tyrosine sulfation post-
translational modification in the HCDR3 loop which allows accurate mimicry of the HIV co-
receptor CCR5, which also contains a sulfated tyrosine (Choe et al., 2003; Huang et al., 
2004). 
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CHAPTER II 
 
RATIONALE AND EXPERIMENTAL DESIGN 
 
History of HIV Vaccination 
 
Since Edward Jenner's success with smallpox immunization in 1796, there have 
been dramatic immunization-related reductions in disease incidence for a number of viral 
diseases including smallpox, polio, measles, mumps, rubella, hepatitis B, and influenza. For 
each of these, protection has been achieved by mimicking infection with the pathogen and 
thereby establishing immunologic memory that can rapidly respond should an actual 
infection occur. This has been perhaps best achieved with the use of live attenuated virus 
vaccines, such as the mumps and measles vaccines, which infect the host but do not cause 
disease and induce strong and long-lasting immune responses. A second successful 
approach involves the use of killed virus vaccines, an example of which is the Salk polio 
vaccine, used in the first widespread polio vaccination campaigns in the mid-1900’s. A third 
approach, referred to as a subunit vaccine, employs exposure of the immune system to 
recombinant viral proteins alone, as in the highly successful hepatitis B vaccine. 
The goal of each of these vaccination strategies is to have an immunologic barrier in 
place that will prevent infection or, failing that, minimize symptoms of disease caused by 
virus infection. Successful vaccines have typically been generated against pathogens for 
which the immune response prevents serious disease in a substantial fraction of those 
infected. Remarkably, knowledge of how vaccine barriers function to protect against 
infection remains limited. What is known is largely built upon observations from animal 
models but, although these are widely accepted as relevant to human vaccines, direct 
mechanistic evidence for how any vaccine works in humans is sparse. 
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The main gatekeeper in most vaccination strategies is thought to be neutralizing 
antibody. Preexisting serum or mucosal antibody induced by an earlier infection or through 
vaccination can bind to free virus particles, prevent viral entry to host cells, and therefore 
prevent the establishment of infection. Even if some host cells are infected, antibody can 
bind to such cells, trigger their elimination via host effector systems, and perhaps contribute 
to aborting infection. Immunity generated in these types of scenarios is termed “sterilizing”, 
and neutralizing antibodies administered intravenously or through mucosal routes can alone 
provide sterilizing immunity against several viruses in experimental animal models. 
Realistically, for most human vaccines, antibodies are unlikely to provide sterilizing 
immunity. Rather, they limit the initial burst of virus replication such that it can then be 
contained by ongoing immune responses without substantial disease symptoms, which is 
the most likely mechanism for most successful vaccines. 
The tremendous global success with other viral vaccines raises the question as to 
why HIV vaccine development has been so difficult. Many of the difficulties lie in distinct 
properties of this virus compared with other viruses. Foremost among these is HIV's 
enormous sequence diversity. Because of an error-prone reverse transcriptase, a high 
propensity for recombination, and an extremely rapid turnover in vivo, HIV's capacity for 
mutation and adaptation is enormous. Viruses even within the same HIV clade may differ by 
up to 20%, and in places such as Africa where there are multiple subtypes, circulating 
viruses can differ within the highly variable envelope protein by up to 38%. Indeed, the 
amount of HIV diversity within a single infected individual can exceed the variability 
generated over the course of a global influenza epidemic, the latter of which results in the 
need for a new vaccine each year. With more than 33 million people currently infected with 
HIV, and the need for a vaccine that simultaneously protects against all potential exposures, 
HIV sequence diversity alone represents a staggering challenge. 
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Early vaccine trials, including the much-publicized Vaxgen trial, used HIV Env-based 
immunogens and were designed to elicit sterilizing immunity through the induction of 
neutralizing antibodies. Passive transfer of neutralizing antibodies had been shown 
protective, so the induction of neutralizing antibodies with similar potency was seen as an 
attractive route to protection. These early vaccines were able to generate antibody 
responses against the Env protein, but these responses were non-neutralizing and thus 
unable to protect against infection. This was not wholly unsurprising, since the majority of 
anti-HIV antibodies in the serum of HIV-infected individuals are directed against non-
neutralizing epitopes or epitopes that are not present on the mature Env trimer. 
In part because of the apparent difficulties in eliciting neutralizing antibodies through 
vaccination, the field switched its focus away from vaccines that induce sterilizing immunity 
toward those that control viral load after infection and thus reduce secondary transmission. 
This shift was prompted by data showing that T cell–mediated immunity was critical for 
resistance to immunodeficiency viruses. For example, depletion of CD8+ cells in simian 
immunodeficiency virus (SIV)-infected macaques led to a resurgence of viral load, and in 
HIV-infected individuals known as “elite controllers,” the control of viral load was associated 
with potent and broad cellular immune responses. Unfortunately, the STEP HIV vaccine 
trial, which was designed to induce a strong CD8+ response through the use of an 
adenovirus (Ad5) vector, failed to protect Ad5-seronegative individuals from HIV infection 
and may have enhanced the likelihood of infection in individuals with previous adenovirus 
exposure. 
 
Rationale 
 
The failure of the STEP trial, which tested the viability of inducing CD8+ responses to 
HIV, has renewed interest in the development of vaccines and immunogens designed to 
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elicit broadly neutralizing antibody responses. The failure of the early HIV vaccines, 
however, has taught us valuable lessons about the importance of careful immunogen design 
in order to focus the immune response on epitopes of interest and to minimize non-
neutralizing antibody responses. Over the past several years, intense effort has been 
expended in the search for HIV bnAbs, with the goal of more fully understanding neutralizing 
epitopes and the mechanisms of neutralization. At the beginning of my thesis research, after 
studying the moderate successes and nearly complete failures of various HIV vaccine trials, 
I thought that a completely new approach to vaccine development might be necessary. This 
new approach, instead of relying on mimicry of viral proteins or viral epitopes, would require 
immunogens designed to rationally guide a naïve antibody, specifically the unmutated 
progenitor of an HIV bnAb, toward the affinity matured, broadly neutralizing antibody. There 
are several immediate objections to this sort of vaccination strategy, each of which, if 
correct, would render such a vaccination scheme close to impossible. First, detailed 
knowledge of the HIV-uninfected antibody repertoire would be necessary, and a massive 
database of antibody sequences from several individuals would be required to accumulate a 
sufficiently detailed understanding of the HIV-uninfected antibody repertoire. A strategy 
designed to rationally mutate a germline antibody sequence toward a broadly neutralizing 
antibody sequence must, by definition, understand the genetic and structural detail of both 
the germline and the broadly neutralizing antibody. Therefore, a deep and comprehensive 
understanding of the HIV-uninfected repertoire is paramount. Second, HIV bnAbs often 
contain genetic or structural features that are extremely uncommon. These features, 
including extensive somatic hypermutation, SHA indels and long HCDR3 loops, may be 
generated only after years or decades of constant antigen exposure, which accompanies 
chronic HIV infection. If these genetic features, which are critical to the neutralizing potency 
of most bnAbs, require antigen exposure over a long time period, it is unlikely that a brief 
vaccination regimen will be able to effectively elicit the required bnAbs. Finally, since very 
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few bnAbs have been discovered and since broadly neutralizing serum activity is rare even 
in HIV-infected individuals, it has been postulated that most people are incapable of 
generating the unique genetic and structural features that are commonly found in bnAbs. 
Under this assumption, the rarity of HIV bnAbs is explained primarily by the rarity of 
individuals capable of generating them and a vaccine designed to induce such antibodies 
would only be effective in a small subset of the population.  
The design of an immunogen the effectively elicits bnAbs is a monumental task, and 
one that would extend far past the time constraints of a PhD thesis. My thesis work focused 
on the fist step of such a process: the determination of whether or not the three objections 
discussed above are valid. 
 
Experimental Design 
 
High throughput antibody repertoire sequencing 
To effectively evaluate the validity of the three objections detailed previously, an 
extremely detailed analysis of the human antibody repertoire is required. During my studies, 
advances in high throughput sequencing technology made such analyses possible. 
Specifically, the 454 sequencing platform, which enables the simultaneous sequencing of up 
to 1 million DNA fragments, released the equipment and reagents necessary for read 
lengths of up to 500 bases per fragment. Although this read length is not comparable to 
Sanger sequencing, for which 1200 base reads are often possible, it is sufficient for 
complete coverage of an antibody heavy chain variable region, which is approximately 
400bp in length. Although sequencing advances made antibody repertoire sequencing 
possible, two major hurdles remain: quantitative amplification of a diverse repertoire of 
antibody sequences, and bioinformatics analysis of the sequencing results. 
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Quantitative primer design 
In order to perform a valid quantitative analysis of the human antibody repertoire, it is 
imperative that the initial PCR amplification of the antibody variable regions be 
accomplished with as little primer-induced bias as possible. This is no small feat: there are 
55 functional variable genes and 6 joining genes, which makes multiplexed primer design 
extremely complex. Further, somatic hypermutation within the primer-annealing region 
would skew amplification away from a subset of somatically mutated sequences and provide 
a misleading picture of the overall antibody repertoire. In order to identify primers that 
produce as little bias as possible, I sampled several dozen multiplexed sets of primers for 
evidence of primer bias. Through this exhaustive sampling process, I identified a single set 
of primers for which the identified germline gene repertoire of the amplification product 
consistently matched that of individually amplified, single sorted B cells, the gold standard of 
repertoire analysis. Further, the variable gene primer-annealing region is in framework 
region 1 (FR1), which is highly conserved among variable gene families and is infrequently 
the target of somatic hypermutation. 
 
Development of a sequence analysis pipeline 
After resolution of the primer bias issue, another technological hurdle still remains. 
Although high throughput sequencing is not new and although many tools exist to analyze 
and process the resulting mountain of data, there are no antibody-specific analysis tools 
capable of handling the enormous amount of data generated by even a single high 
throughput sequencing run. A flexible database structure and schema must also be 
developed, preferably using industry-standard database software, which will enable rapid 
identification of sequences that fit desired search criteria. Several software packages exist 
which allow identification of putative germline genes from an antibody sequence, as well as 
a varying amount of somatic mutation analysis. One of the gold-standard tools of the 
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antibody field, the IMGT-V/QUEST webserver, allows batch upload of a maximum of 50 
sequences. This is obviously not feasible when the sequence pool to be analyzed contains 
hundreds of thousands of sequences. I was afforded the opportunity, however, to be among 
a group of researchers selected by IMGT to beta test a new version of the webserver, 
HighV-QUEST, which was specifically designed to accommodate high throughput antibody 
sequencing and allows batch upload of up to 150,000 sequences at a time. In total, the 
HighV-QUEST webserver has enough computational power to analyze approximately 8 
million antibody sequences in 24 hours. I have also created a custom relational database 
using MySQL database software. MySQL is an open-source implementation of the industry-
standard Structured Query Language (SQL), a programming language designed specifically 
for managing data in relational database systems. The database is designed so that the 
output from the HighV-QUEST webserver can be directly imported into the database and 
rapidly queried. Although the learning curve for programming in MySQL is steep, it offers 
extraordinary speed and flexibility when handling very large relational data sets. 
 
Selection of bnAbs for analysis 
 In order to evaluate the presence and frequency of germline precursors of bnAbs in 
the HIV-uninfected repertoire, one or more bnAbs must first be selected for analysis. 
Selecting the proper bnAb for which to search for germline precursors is critical, because 
some of the bnAbs that have been discovered may be very difficult or impossible to induce 
in a large segment of the population. Others may be difficult to generate through a 
vaccination regimen of feasible duration. I have previously shown that bnAbs typically have 
either extensive somatic hypermutation or encode a long HCDR3 loop. Antibody sequences 
with extensive somatic hypermutation are, by definition, quite distinct from any possible 
germline precursor. The feasibility of generating such extensive somatic hypermutation 
through vaccination has not been shown; it is likely to be very difficult and will potentially 
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involve more than simply immunogen design. It has been speculated that, through the use 
of yet-to-be-determined adjuvants, the rate of somatic hypermutation may be altered such 
that a large number of somatic mutations can be rapidly induced with a small number of 
inoculations. This is yet to be shown, however, and even a temporary alteration in the rate of 
somatic hypermutation may have substantial unintended effects. 
On the other hand, antibodies with long HCDR3s may already be present in the 
naïve, or unmutated, B cell population. Selection of pre-existing antibodies encoding long 
HCDR3 loops from the germline repertoire would, in theory, only require design of the 
proper immunogen for selection of bnAb precursors. For this reason, we selected two 
somatically-related bnAbs, PG9 and PG16, which use exceptionally long HCDR3s as the 
primary mechanism of binding and neutralization. These antibodies are not extensively 
somatically mutated and most residues that are critical to binding and neutralization are 
encoded in the germline sequence, raising the intriguing possibility that germline precursors 
to these bnAbs, if they are found to be present in HIV-uninfected individuals, may have 
some level of binding and/or neutralization capacity even without somatic hypermutation. 
Thus, elicitation of PG-like neutralizing antibodies may require only minimal somatic 
hypermutation. 
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CHAPTER III 
 
GENETIC ANALYSIS OF THE HUMAN ANTIBODY REPERTOIRE IN PERIPHERAL 
BLOOD AND MUCOSAL AND LYMPHOID TISSUES 
 
Introduction 
 
A diverse human antibody repertoire is a key element of the acquired immune 
response and is critical to the effective prevention and clearance of microbial infections 
(Crotty and Ahmed, 2004). Vast diversity in the antibody repertoire is generated initially 
through a process of combinatorial rearrangement in which variable (V), diversity (D), and 
joining (J) gene segments are assembled into a complete immunoglobulin sequence 
(Tonegawa, 1983; Schatz et al., 1989). This initial diversity is increased through the use of 
antigen-driven somatic hypermutation and class-switch recombination (Neuberger and 
Milstein, 1995; Wilson et al., 1998a; Neuberger, 2008; Schroeder and Cavacini, 2010). 
These affinity maturation processes result in the creation of distinct memory populations that 
contain only antigen-experienced B cells (Jackson et al., 2008). 
Previous analysis of the antibody gene repertoire in peripheral blood B cell subsets 
did not detect significant differences in germline V, D or J gene segment usage between the 
naïve and memory populations (Tian et al., 2007). This finding was somewhat surprising, 
since it was expected that the memory subset might contain an altered germline gene 
repertoire that was biased by antigen selection. Although more narrowly focused work was 
previously able to identify differential JH gene use in memory subsets (Rosner et al., 2001), 
this study only analyzed the fraction of sequences that contain the VH6 gene segment and 
not the total repertoire. A study using a larger sequence pool was able to identify differences 
in both JH gene and VH gene family use in naïve and memory subsets, with the memory 
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population displaying an increase in JH4 gene use, a corresponding decrease in JH6 gene 
use, and differential use of several VH gene families (Wu et al., 2010b). During my studies, 
there were several studies that leveraged high throughput amplicon sequencing to perform 
in-depth analysis of human antibody repertoires (Boyd et al., 2009; 2010; Wu et al., 2010b; 
Arnaout et al., 2011; Prabakaran et al., 2011). These previous studies have been limited in 
scope, however, due to analysis of the use of V, D or J genes in isolation. In the peripheral 
blood antibody repertoire, individual V, D and J genes are not expressed in isolation, but are 
linked by recombination. Thus, it is imperative to study gene segment usage not only by 
individual gene segment use, but also in the context of complete V(D)J pairings to gain a 
more complete understanding of the antibody repertoire. Here, I present a thorough 
examination of V(D)J recombinants in the human peripheral blood repertoire. The studies 
reveal stark repertoire differences between circulating B cell subsets and provide genetic 
evidence for global control of repertoire diversity in both naïve and memory subsets. 
Although repertoire differences between the peripheral blood B cell subsets have 
been identified, the overall peripheral blood repertoires were more similar than expected. 
Since each individual has experienced a unique progression of pathogenic encounters and 
since these pathogenic encounters have been shown to elicit antibody responses with 
skewed repertoires (Tian et al., 2007; 2008), the resulting memory B cell subsets would be 
expected to be equally unique in each individual. This raises the possibility that many 
antigen-specific cells reside in locations other than the peripheral blood. From an 
immunological perspective, this makes sense; having the appropriate memory responses 
located at the most common sites of pathogen encounter would aid in the rapid generation 
of a robust antibody response.  
The antibody repertoires of mucosal tissues have been previously shown to consist 
predominantly of class-switched B cells and that these B cells are antigen-specific 
(Benckert, 2011). In general, IgA is the most abundant antibody isotype at mucosal 
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surfaces, although IgG and IgD make up a substantial portion of mucosal secretions (10, 18, 
19). In addition, IgE is measurable in several mucosal secretions when allergy is present 
(37). Although the isotype composition of mucosal tissues is fairly well studied, little is 
known about the genetic repertoire composition of the tissue antibody repertoires. 
 
Genetic Analysis of the Human Healthy Donor Antibody Repertoire 
 
With assistance from the Vanderbilt Flow Cytometry core, we separately isolated 
naïve, IgM memory and IgG memory B cells from four healthy individuals using flow 
cytometric sorting, extracted mRNA and performed RT-PCR to amplify antibody genes from 
those cells, and subjected the resulting amplicons to high throughput DNA sequencing. The 
primers were selected for their ability to produce accurate, reproducible amplification of both 
naïve and mutated antibody repertoires (Boyd et al., 2009; 2010), and the variable gene use 
of our repertoire closely matched repertoire analysis in which amplification was performed 
on single B cells (Tian et al., 2007; 2008). After selecting only high-quality antibody 
sequences, we obtained a total of 294,232 naïve cell sequences, 161,313 IgM memory cell 
sequences and 94,841 IgG memory cell sequences. 
I analyzed the V(D)J recombinant repertoire in each of the three B cell subsets, and 
created Circos plots showing the relative prominence of each V(D)J recombination within 
the repertoire of each cell subset (Figure 8A-C). These plots revealed a large number of 
trends that were apparent only when analyzing the repertoire in the context of complete 
V(D)J recombinations. In this chapter, I will focus on three of the most prominent trends.  
First, virtually all of the major VH-JH pairings (identified by colored ribbons in Figure 8) 
follow a similar pattern: increased use of VH-JH pairings that contained heavy chain joining 
gene 4 (JH4) and decreased use of pairings that contained JH5 or JH6 in both memory 
subsets, as compared to naïve cells. Use of JH4 has been shown previously to be increased  
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Figure 8. Circos diagrams display linked VH, D, and JH gene use in naïve, IgM memory or IgG memory B 
cell subsets. Circos plots were generated for (A) naïve, (B) IgM memory, or (C) IgG memory repertoires. On 
the right half of each plot (colored segments), each heavy chain variable gene family is shown in a separate 
color. The arc length of each segment corresponds the relative frequency of each heavy chain variable (VH) 
gene family in the identified B cell subset. The smaller ticks on the outer ring represent 1,000 sequences, with 
major ticks marking 5,000 sequences. The left half of each plot (black segments) shows each heavy chain 
joining (JH) gene segment. The arc length of each segment corresponds to the frequency of JH gene use in 
combination with the given VH gene within the identified subset. The scale of arc lengths on the JH gene side 
of the diagram is 1/4 that of the arcs on the VH gene side. Just inside the tick ring on the VH gene side of the 
diagram, segmented arcs identify the individual VH genes within each VH gene family. Within each plot, 
pairing of JH genes to VH gene segments is represented by colored ribbons. The color of the ribbon indicates 
VH gene use; increased ribbon width and color intensity corresponds to increased frequency of the 
represented VH-JH pairing. Just outside the VH-JH links on the VH gene side of the diagram, a stacked 
histogram indicates D gene use for each VH-JH pairing.  Diversity gene families D1, D2, D3, D4, D5, D6 and 
D7 are plotted in increasingly darker shades of grey (D1 is closest to the center in lightest grey; D7 is furthest 
from the center in darkest grey). (D) The contribution of the fifty most common V(D)J recombinations for each 
subset is plotted.  Bars indicate mean ± SEM. The p values for pairwise comparisons were determined using a 
two-tailed Student’s T test. 
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in memory subsets (Wu et al., 2010b), but the consistency with which the broad spectrum of 
VH-JH pairings exhibited increased JH4 use is surprising. Second, use of diversity gene 
family 3 (D3) was increased dramatically in recombinations that used heavy chain variable 
gene 3-30 (VH3-30) and either JH4 or JH5 in both naïve and IgG memory subsets. In the IgM 
memory cell subset, however, diversity gene use in recombinations that used VH3-30 and 
JH4 or JH5 was much lower than in the naïve or IgG memory subsets and was comparable to 
that of other genes in the VH3 family. These data support emerging evidence that the IgM 
memory repertoire is genetically distinct from the IgG memory repertoire and that this 
difference is likely the result of different stimuli (Tian et al., 2007; Wu et al., 2010b). Finally, 
the three Circos plots reveal the increased oligoclonality of both memory subsets compared 
to naïve. The colored ribbons in each plot represent VH-JH pairings that comprise at least 1% 
of the total subset repertoire. In the naïve subset, there are 66 different VH-JH pairings that 
each account for at least 1% of the total naïve repertoire. In the IgM memory subset, only 27 
different VH-JH pairings exceed 1% of the total subset repertoire, and only 19 VH-JH pairings 
exceed 1% in the IgG memory subset. These data indicate that the memory subsets 
become increasingly oligoclonal, with a small selection of VH-JH pairings comprising a larger 
fraction of the total subset repertoire. 
Further analysis of the variable gene use in each of the subsets revealed contrasts 
with recently published work on the antibody repertoire in human cord blood (Prabakaran et 
al., 2011). In the cord blood repertoire, VH1-2 was found to be the most commonly used 
germline gene. In the naïve, IgM memory and IgG memory subsets, not only was VH1-2 not 
the most commonly used variable gene, it was not even the most commonly used VH1 family 
gene. Both VH1-18 and VH1-69 were more frequently used in the naïve and IgG memory 
populations and VH1-18 was used more frequently in the IgM memory population. In all three 
peripheral blood subsets, either VH3-23 (naïve and IgM  
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memory) or VH3-30 (IgG memory) was the most commonly used variable gene, which is 
consistent with previous data (Boyd et al., 2009; 2010; Wu et al., 2010b; Arnaout et al., 
2011).  
The oligoclonality of each subset was further analyzed by determining the 
contribution of the 50 most commonly used V(D)J recombinations to the total repertoire of 
each subset (Figure 8D). In the IgG memory subset, which was most oligoclonal, the top 50 
V(D)J recombinations accounted for 38.2% of the subset repertoire. Conversely, in the 
naïve and IgM memory subsets, which were significantly less oligoclonal than the IgG 
memory subset, the top 50 V(D)J recombinations accounted for only 19.6% (naïve, p=0.01) 
or 23.6% (IgM memory, p=0.02) of the total subset repertoire. Additionally, there was a trend 
toward reduced oligoclonality in the naïve subset compared to IgM memory that fell short of 
statistical significance (p=0.15). 
Figure 9. Clustergram of V(D)J recombinants reveals global control of expressed antibody repertoires in 
B cell subsets. The frequency of each V(D)J recombination was determined for the naïve, IgM memory or IgG 
memory subsets for four healthy donors, and a clustergram was created. V(D)J recombinants were clustered by 
relative frequency in each donor and subset, and the resulting phylogenetic tree is shown on the left. Results for 
three B cell subsets from each donor were clustered by the V(D)J repertoire, and the resulting phylogenetic tree 
is shown at the top. The frequency variation for each V(D)J recombination across all subsets was determined, 
and standardized to a range of -3 to 3. The colorimetric scale for the heat map is shown. 
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With assistance from Brett McKinney, we next performed a clustering analysis on the 
V(D)J recombinant repertoire for each donor and subset (Figure 9). We found patterns that 
were robust to different clustering metrics and linkage types. Specifically, Brett performed 
hierarchical bi-clustering with the Euclidean and Pearson correlation metric in combination 
with single linkage, complete linkage and average linkage. In all scenarios, the samples 
clustered in the categories shown in Figure 9. Prior to clustering a variance filter was used to 
remove genes with very low variation across subjects. Interestingly, repertoires of the same 
subset from different donors (inter-donor subsets) were more closely related than different 
subset repertoires from the same donor (intra-donor subsets). In fact, phylogenetic 
clustering of the subset repertoires of all four donors revealed clustering exclusively among 
inter-donor subsets, with no observed intra-donor subset clustering. This finding was 
unexpected, since each donor has experienced a unique set and sequence of pathogen 
encounters, and each donor might be expected to generate unique memory repertoires 
appropriately skewed by prior histories of infection. Also of note, donor pairs were 
consistently clustered together, regardless of subset. Donors HD4 and HD5 clustered most 
closely in each of the three subsets, as did donors HD6 and HD7. In addition to the inter-
clonal subset clustering, the tight groupings of highly over-represented V(D)J 
recombinations within each individual memory repertoire provide further evidence of the 
oligoclonality of the memory subsets. The unique V(D)J recombinations that comprise the 
tight groupings are not shared between like subsets of different donors and, surprisingly, 
similar groupings are not present in the naïve subset from the same donors. This finding 
indicates that while the frequency of germline gene family use may appear similar between 
naïve and memory populations when the VH , D or JH families are analyzed in isolation, 
deeper analysis of the V(D)J recombinant repertoires of these subsets uncovers stark 
repertoire differences.  
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The substantial differences in each subset repertoire at the individual V(D)J 
recombinant level, coupled with the overarching similarities of the repertoires at the germline 
gene family level, present something of a paradox. These data seem to suggest the 
presence of a broad, global mechanism for repertoire regulation at the germline gene family 
level. While there is no direct evidence of such a mechanism, several recent studies indicate 
the presence of repertoire-based regulatory mechanisms in circulating B cell subsets. 
Despite the tendency of pathogen-specific antibody responses to exhibit biased germline 
gene repertoires (Weitkamp et al., 2005; Tian et al., 2008; Gorny et al., 2009), the frequency 
of gene family use in naïve and memory subsets is remarkably consistent across individuals 
(Tian et al., 2007; Wu et al., 2010b). Further, alteration of this gene family homeostasis in 
the circulating B cell repertoire is associated with disease states (David et al., 1995; 1996; 
Zouali, 1996; Scamurra et al., 2000). In recent work, long-lived plasma cells were shown to 
contain significantly fewer autoreactive B cells than the circulating IgG memory subset, and 
this difference was attributed to differential repertoire regulation within the two subsets 
(Scheid et al., 2011). Thus, while no mechanism for regulation of circulating human antibody 
repertoires has been identified, mounting indirect evidence, including the data presented in 
this report, suggests the presence of such regulation. 
 
Differences Between Peripheral Blood and Mucosal and Lymphoid Tissue Antibody 
Repertoires 
 
Antibody variable gene use  
I obtained total RNA from a variety of tissue samples derived from a pool of donors: 
peripheral blood leukocytes, bone marrow, small intestine, lung, stomach, lymph node, 
tonsil, spleen and thymus. The expressed antibody variable genes were amplified using RT-
PCR, and the resulting amplicons were subjected to high-throughput DNA sequencing. After  
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Figure 10. Antibody variable gene family usage in peripheral blood or tissues. Antibody variable gene 
family usage is shown for each sample as a percentage of the total sample antibody repertoire. VH3 was the 
most common variable gene family used in six of the eight samples. VH7 was the least common variable gene 
family used in seven of the eight samples. To facilitate comparison between tissues and peripheral blood, a 
vertical grey line indicates the peripheral blood frequency for each variable gene family. 
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selecting only high-quality, non-redundant antibody sequences, I obtained a total of 
1,412,943 sequences. 
 I first determined the frequency of use of each antibody variable gene family in each 
tissue (Figure 10), and discovered substantial differences in the gene family use in tissues 
compared to that in peripheral blood. A large number of differences were noted; I focus here 
on three of the most prominent trends. First, heavy chain variable gene family 2 (VH2) use 
was increased in every tissue except for small intestine. VH2 was found in 7.7% of peripheral 
blood sequences, and the largest increases were found in bone marrow (13.8%), thymus 
(12.5%) and lymph node (12.3%). Second, while VH3 was the most common variable gene 
family in most of the samples, the lung and thymus samples used the VH4 family more 
frequently than VH3. Finally, repertoires in mucosal sites (stomach, lung, small intestine) 
differed significantly from that in lymphoid tissues (lymph node, spleen, tonsil, thymus). Each 
Figure 11. Clustergram of antibody repertoires. The frequency of each V(D)J recombination was determined 
for each of nine tissues, and a clustergram was created. V(D)J recombinants were clustered by relative 
frequency in each tissue-specific repertoire, and the resulting phylogenetic tree is shown on the left. Tissue-
specific repertoires were clustered by the overall V(D)J usage of each repertoire, and the resulting phylogenetic 
tree is shown at the top. The frequency variation for each V(D)J recombination across all tissue-specific 
repertoires was determined, and standardized to a range of -3 to 3. The colorimetric scale for the heat map is 
shown.  	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of the four lymphoid tissue samples showed 
reduced use of the VH3 family compared to 
peripheral blood, while two of the three mucosal 
tissues showed increased use of VH3 family 
genes. Similarly, each of the three mucosal 
samples showed reduced VH6 gene family use 
compared to peripheral blood, but three of the 
four lymphoid tissue samples used VH6 more 
frequently than peripheral blood. Analysis of the 
diversity (D) gene family and heavy chain 
joining (JH) gene use within each variable gene 
family produced similar trends for both the 
mucosal and lymphoid groups.  
 
Differences in the recombined VH(D)JH 
repertoire 
I next performed a clustering analysis on the recombined VH(D)JH repertoire for each 
tissue sample (Figure 11). Interestingly, the repertoire in lymphoid tissues (tonsil, spleen, 
lymph node and thymus) clustered with each other and with peripheral blood. Repertoires 
from mucosal tissues (lung, small intestine, stomach) also clustered together, along with 
bone marrow. This finding indicates that the recombined VH(D)JH repertoires of mucosal 
tissues differ substantially from both peripheral blood and lymphoid tissues.  
To more closely investigate these repertoire differences, I first determined the 
germline gene use in each recombined VH(D)JH sequence in each tissue by calculating the 
frequency of each VH(D)JH combination. I then compared these frequencies to that in the 
Figure 12. Comparison of V(D)J use in 
lymphoid and mucosal tissues to 
peripheral blood. (A) The frequency of each 
V(D)J recombination was calculated for each 
tissue and compared to peripheral blood. (B) 
The frequency of each V(D)J recombination 
was determined for each tissue and 
compared to peripheral blood. The log10 fold 
change of the 50 most different V(D)J 
recombinations is shown for each tissue. 
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pooled peripheral blood sample (Figure 12A). I found a trend toward more differences 
between mucosal tissues and peripheral blood than were present between lymphoid tissues 
and blood (p=0.079). I also analyzed the magnitude of the top 50 differences from peripheral 
blood for each of the mucosal and lymphoid samples (Figure 12B), and found that 
differences in VH(D)JH frequency between mucosal tissue samples and peripheral blood 
were significantly larger than differences between lymphoid tissue samples and peripheral 
blood (p=0.039).  
 
Mutation frequency analysis 
Sequences from each tissue subset were grouped by mutation frequency, and a 
mutation histogram was created for each tissue sample (Figure 13A). The peripheral blood 
sample contained a large number of sequences with few or no mutations, which is 
consistent with the previous reports that the peripheral blood B cell compartment contains a 
large proportion of naïve cells (Wu et al., 2010b; Briney et al., 2012b). In contrast, the bone 
marrow sample contained very few sequences with few or no mutations, which is somewhat 
surprising, since bone marrow contains many progenitor and precursor B cells, which are 
presumably unmutated. The absence of unmutated sequences is likely due to the use of 
mRNA as template for the antibody gene amplification. Since bone marrow resident long-
lived plasma cells transcribe the antibody gene at a much higher rate than immature B cells 
(Smith et al., 2009), it is likely that oversampling of plasma cell expressed sequences in the 
amplified mRNA skewed the bone marrow sequence repertoire toward highly mutated 
sequences.  
All three mucosal tissue samples (small intestine, stomach and lung) showed a 
dramatic paucity of sequences with few or no mutations, indicating that naïve B cells are 
less frequent in tissue. Interestingly, each of the lymphoid tissues (lymph node, tonsil, 
spleen and thymus) contained a higher frequency of antibody genes with few or no 
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mutations (7.0%) than mucosal tissues (1.4%; p=0.03), but a lower frequency than 
peripheral blood (30.6%; Figure 13B). A more detailed breakdown of mutation frequency by 
antibody gene region (Figure 13C) showed a reduction in mutation frequency in lymphoid 
tissue repertoires across all framework regions (FRs) and complementarity determining 
regions (CDRs) when compared to mucosal tissue repertoires (p=0.0002). 
 
Mucosal tissue repertoires encode longer HCDR3s than lymphoid tissue repertoires 
Sequences from each tissue repertoire were grouped by HCDR3 length and the 
frequency of each HCDR3 length group was determined (Figure 14A). To ease 
comparisons, the HCDR3 length histogram for the peripheral blood repertoire is displayed 
Figure 13. Mutation frequency for peripheral blood, bone marrow and mucosal and lymphoid tissues. 
Mutation histograms are shown for each sample. Sequences for each tissue sample were grouped by the 
number of somatic mutations, and the frequency of each mutation count was determined. To ease comparisons 
between tissue samples and peripheral blood, the mutation histogram for peripheral blood is shown as a dashed 
line on each plot. 
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alongside each tissue HCDR3 histogram. Tissue repertoires then were divided into two 
groups based on HCDR3 length: short HCDR3s (≤14 amino acids) and long HCDR3s (≥15 
amino acids) (Figure 14B). The repertoires of lymphoid tissues were split approximately 
evenly between short (50.7%) and long (49.3%) HCDR3 lengths. In contrast, repertoires 
from mucosal tissues contained a significantly higher frequency of long HCDR3s (58.4%) 
and a significantly lower frequency of short HCDR3s (41.6%) than lymphoid repertoires 
(p=0.02). Further, the overall mean HCDR3 length of the mucosal tissue repertoires was 
significantly longer than the overall mean HCDR3 length of lymphoid tissue repertoires 
(Figure 14C; p=0.035). This finding was surprising since mucosal repertoires contain a 
Figure 14. Mucosal tissue repertoires encode longer CDR3s and are more mutated than lymphoid tissue 
repertoires. (A) The mean CDR3 length was determined for each repertoire.  Bars indicate mean ± SEM. (B) 
The mean mutation frequency was determine for each repertoire. Bars indicate mean ± SEM. 
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higher fraction of highly mutated 
sequences than lymphoid repertoires 
(Figure 13), but there are reports that 
highly mutated memory B cell subsets 
may encode shorter HCDR3s than the 
unmutated naïve subset (Wu et al., 
2010b). Since long HCDR3s tend to 
have a lower frequency of hydrophobic 
and charged residues (Wu et al., 
2010b), we determined the frequency 
of both hydrophobic and charged 
HCDR3 residues in mucosal and 
lymphoid repertoires (Figure 14D). 
While there was a trend toward 
reduced frequency of hydrophobic 
HCDR3 residues in the mucosal tissue 
repertoires compared to lymphoid 
repertoires (p=0.13), there was no 
difference in the frequency of charged 
HCDR3 residues in mucosal 
repertoires (23.4%) compared to 
lymphoid repertoires (23.2%; p=0.61).  
 
Somatic hypermutation-associated 
insertions and deletions 
Figure 15. Frequency and position of DNA fragments 
encoding non-frameshift insertions. (A) The presence and 
frequency of non-frameshift insertions is shown in peripheral 
blood. The location of CDR1 and CDR2 are highlighted in grey. 
(B) The difference in insertion frequency when compared to 
peripheral blood is shown for each tissue. As before, CDR1 
and CDR2 are highlighted in grey. 
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 Short nucleotide insertions 
or deletions (abbreviated: indels) 
are associated with the somatic 
hypermutation process (Wilson et 
al., 1998b), and antibodies 
encoding these somatic 
hypermutation-associated indels 
(SHA indels) have been shown 
critical to the immune response 
against pathogens that initiate 
infection at mucosal surfaces (Wu 
et al., 2010a; Krause et al., 2011; 
Walker et al., 2011). The heavy 
chain sequences for antibodies 
from all tissue repertoires were 
analyzed for the presence of 
codon-length nucleotide indels in 
the antibody variable gene region. 
Sequences from the peripheral 
blood repertoire containing SHA 
indels were analyzed further to 
determine the location of each indel, 
and the frequency of insertions (Figure 
15) or deletions (Figure 7) at each 
codon position of the variable gene 
Figure 16. Frequency and position of DNA fragments 
encoding non-frameshift deletions. (A) The presence and 
frequency of non-frameshift deletions is shown in peripheral 
blood. The frequency is plotted as the percent of sequences in 
the repertoire displaying deletions at each codon position. The 
location of CDR1 and CDR2 are highlighted in grey. (B) The 
difference in deletion frequency when compared to peripheral 
blood is shown for each tissue. As before, CDR1 and CDR2 
are highlighted in grey. 
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was calculated. For each additional tissue repertoire, the difference in frequency, compared 
to peripheral blood, was calculated at each codon position. Insertions and deletions were 
both located predominantly in CDRs as opposed to frameworks, and were roughly equally 
distributed in location between heavy chain CDR1 (HCDR1) and HCDR2.  
A large increase in frequency of both insertions and deletions in the small intestine 
antibody repertoire was noted. This finding was even more surprising since the frequency of 
SHA indels correlates with the frequency of somatic hypermutation events (Wilson et al., 
1998b), and a corresponding increase in somatic mutations was not observed in the small 
intestine antibody repertoire (Figure 13A). The presence of a large increase in SHA indel 
frequency without a corresponding increase in mutation frequency suggests that increased 
frequency of SHA indels in the small intestine antibody repertoire likely was not driven 
simply by an overall increase in affinity maturation associated events. Instead, these data 
suggest that SHA indels are enriched specifically in the small intestine repertoire. 
 
Non-12/23 Recombinations in the Human Peripheral Blood Repertoire 
 
Presence and frequency of putative V(DD)J recombinants in peripheral blood B cells 
To limit the number of falsely identified V(DD)J recombinations (that is, 
recombinations with N-addition regions that contain stretches of similarity to diversity 
genes), I developed a stringent filtering procedure. All sequences were analyzed with the 
IMGT High/V-QUEST webserver, with the number of accepted diversity genes set to 2. The 
antibody region identified by IMGT as a putative diversity gene is designated here as the 
“match region” (Figure 17). Our filtering process required the match regions to contain a 
maximum of one nucleotide difference from the germline diversity gene segment. The length 
of the match region, minus any mismatches between the match region and the germline 
diversity gene, is designated the “match score”. The match score, which represents the 
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number of identically matched nucleotides between the match region and the germline 
diversity gene segment, was required to be at least 60% of the overall length of the germline 
diversity gene segment, except in the case of the short IGHD7-27 gene segment for which 
we required a match score of 72% of the germline diversity gene length (8 of 11 
nucleotides). 
The sequences obtained from each of the three cell subsets were examined for the 
presence of junctions containing multiple diversity gene segments using a high stringency 
filtering procedure. The frequency of V(DD)J recombination in each of the three sorted B cell 
subsets is shown in Figure 18A. The mean V(DD)J recombinant frequency in the naïve 
population (0.12%) was more than 10-fold higher than in the IgM memory population 
(0.01%, p=0.0095). Interestingly, the IgG memory population did not contain a single 
predicted V(DD)J recombination event that passed our filtering procedure. It was possible 
that our filtering procedure, which allowed only a single mutation in the match region, 
preferentially rejected prediction of V(DD)J recombinants from the somatically mutated 
memory populations while retaining V(DD)J recombinants in the mutation-free naïve 
population. A less stringent analysis, which allowed mutations, revealed increased V(DD)J  
Figure 17. Stringent filtering of V(DD)J recombinants. A sample V(DD)J recombinant (3FV6DI) is shown, 
along with the germline diversity gene assignments for both the 5′ D (D2-2) and 3′ D (D2-8) positions. Dashes 
indicate conservation between germline and 3FV6DI and dots indicate mismatches. The match region is 
indicated above the 3FV6DI sequence, along with the match score (the match region length minus any 
mismatches within the match region). The germline segment length is shown below the sequence alignment. 
Below the germline segment length, the scoring calculation is shown. Sequences that contained scores of 
>60% for both diversity gene positions were considered V(DD)J rearrangements. 	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recombinant frequency in all subsets including 
IgG memory, but still showed a significant 
reduction in V(DD)J recombination frequency 
in the IgM memory (0.08%, p=0.0077) and 
IgG memory (0.04%, p=0.0048) subsets when 
compared to the naïve subset (0.23%). 
Memory subsets have a reduced frequency of 
long HCDR3 loops (Tian et al., 2007) and the 
V(DD)J population is dominated by long 
HCDR3-containing antibodies (Figure 18B), 
with the average HCDR3 length of 26.5 amino 
acids. 
 
Germline diversity gene usage in putative 
V(DD)J recombinants 
The D gene usage in V(DD)J 
recombinants was compared to D gene usage 
in the total naïve cell repertoire to identify if 
there was a preferential use of particular D 
genes in V(DD)J recombinants (Figure 19). Interestingly, D gene use at the 3′ D position in 
V(DD)J recombinants was very similar to D gene usage in the total naïve repertoire, 
showing only an increase in D7 gene family usage (difference between means of 6.93 ± 
2.58, p=0.036) and an approximately equivalent decrease in D2 gene family usage 
(difference between means of -10.02 ± 2.40, p=0.0058). D gene use at the 5′ D position in 
V(DD)J recombinants showed a significant increase in the D2 gene family (p=0.0022) and a 
Figure 18. Frequency and HCDR3 length of 
putative V(DD)J recombinants. (A) V(DD)J 
recombinant frequency (as a percent of the 
subset repertoire) of naïve, IgM memory or IgG 
memory B cell subsets isolated from the 
peripheral blood of four healthy individuals. The 
V(DD)J frequency for each donor ± SEM for each 
subset is shown. Pairwise comparisons of V(DD)J 
recombinant frequency between different subsets 
were determined using a one-way ANOVA with 
Bonferroni’s correction. (B) Histogram of CDR3 
length distribution of V(DD)J recombinations 
(filled bars). The length distribution for the entire 
repertoire (dashed line) is also shown for 
comparison. ** = p<0.01. 
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significant decrease in the D1, D3 and D4 gene families (p<0.0001, p=0.0132 and p=0.0414, 
respectively). The 5′ D position also showed a strong trend toward increased D5 gene family 
use (p=0.06) and a notable absence of D7 family members. 
 
N-addition length and GC content of V(DD)J recombination sites indicate true D-D fusion 
 While it is highly unlikely that random insertion of nucleotides at the VD or DJ 
junction would result in long sequence stretches that identically match germline diversity 
gene segments, I examined the N-addition lengths of all recombination sites in the total 
peripheral blood repertoire to determine if the N-addition regions flanking both diversity 
genes matched that of the normal V(D)J repertoire. I determined the mean N-addition length 
for all VD and DJ recombination sites in the total repertoire and the VD (also referred to as 
N1), DD (N2), and DJ (N3) recombination sites in the putative V(DD)J repertoire (Figure 
20A). I found that there was no statistically distinguishable difference between the mean 
length of the recombination sites in the total repertoire and in the putative V(DD)J repertoire. 
I next compared the GC content of all N-addition (N) and D gene regions in the total 
naïve repertoire to the GC content of both assigned diversity genes (D1 and D2) and the N1, 
N2 and N3 N-addition sites in the V(DD)J repertoire (which correspond to the VD, DD and 
Figure 19. Diversity gene use in putative V(DD)J recombinants differs from that in the total naïve repertoire. 
Diversity gene family use for the total naïve repertoire (Naïve) or for the 5ʹ′D and 3ʹ′D positions in V(DD)J recombinants. 
Mean ± SEM for each donor is shown. Pairwise comparisons were determined using a two-way ANOVA with 
Bonferroni’s correction. * = p<0.05; ** = p<0.01; *** = p<0.001. 
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DJ recombination sites, respectively) (Figure 
20B). There was a highly significant decrease 
in the GC content of both D1 (p<0.0001) and 
D2 (p=0.0051) regions when compared to the 
N-addition regions in the total naïve 
repertoire. In contrast, neither of the assigned 
D gene segments in the V(DD)J repertoire 
differed from the GC content of assigned D 
genes in the total naïve repertoire, Thus, the 
D1 and D2 regions better resembled the GC 
content of D gene segments than N-addition 
regions.  
D gene order in V(DD)J recombinants matches 
the order of those D genes in the genome.  
I analyzed 5′ D and 3′ D pairings in the 
V(DD)J repertoire and discovered that every 
V(DD)J recombinant contained D-D pairings in 
an orientation that matched the orientation of the 
genomic locus (Figure 21A). I also found that 
V(DD)J recombination occurred across the 
spectrum of D genes, using every D gene with 
the exceptions of D4-11, D4-14 and D6-25. D4-11 (<0.001%), D4-14 (0.895%) and D6-25 
(0.60%) were the least frequently observed D genes in the total repertoire (Figure 5C), so 
the lack of these D genes in the V(DD)J repertoire was likely due to their rarity. As expected, 
the 5′ D position contained a high proportion of D gene segments located at the 5′ end of the 
Figure 20. Putative V(DD)J recombinants 
contain normal N-addition lengths and 
diversity genes, with low GC content. (A) N-
addition length for each recombination site in the 
total naïve repertoire or in the V(DD)J repertoire. 
The mean N-addition length for each of four 
healthy individuals ± SEM is shown for each 
recombination site. (B) GC content (as a percent 
of the region sequence) for each N-addition region 
or diversity gene segment in the V(DD)J repertoire 
or the total naïve repertoire. Combined N-addition 
at the VD and DJ junctions (N) or diversity gene 
region (D) are shown for the total repertoire.  
Diversity genes at the 5ʹ′D position (D1) and 3ʹ′D 
position (D2) and N-addition sites at the VD 
junction (N1), DD junction (N2) and DJ junction 
(N3) are shown for putative V(DD)J recombinants. 
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genomic locus (Figure 21B), with the frequency of D gene presence in the 5′ D position 
decreasing exponentially with distance from the 5′ end of the genomic locus. A similar 
preference for upstream D genes was not seen in when analyzing the frequency of D gene 
use in the entire repertoire (Figure 21C). Only three of the ten furthest downstream (3′) D 
genes were ever found in the 5′ D position of a V(DD)J recombinant. There also was a weak 
 
Figure 21. Genomic orientation of diversity genes matches the orientation in putative V(DD)J 
recombinants and explains diversity gene use bias at 5ʹ′D and 3ʹ′D positions. (A) All functional diversity 
genes are represented in the genomic orientation, with arcs connecting diversity genes found paired in a V(DD)J 
recombinant. Black boxes indicate diversity genes found only in the 5ʹ′D, white boxes indicate diversity genes 
found only in the 3ʹ′D position, and grey boxes indicate diversity genes found in both positions. D4-11, D1-14 and 
D6-25, the only diversity genes not found in any V(DD)J recombinants, are represented by black circles. The 
orientation of diversity genes in V(DD)J recombinants matches the genomic orientation in every instance, so the 
leftmost member of any linked pair of diversity genes shown in this diagram was always in the 5ʹ′D position of the 
V(DD)J recombination. (B) The frequency of each diversity gene in either the 5ʹ′D or 3ʹ′D positions is shown with 
the diversity genes ordered and labeled by position from the 5ʹ′ end of the genomic locus. (C) The frequency of 
each diversity gene in the total repertoire (including all B cell subsets). Shown are the mean frequency ± SEM for 
each donor. (D) The frequency of each recombination span, defined as the distance between the 5ʹ′D gene and 
the paired 3ʹ′D gene in V(DD)J recombinants (measured in diversity gene segments and including non-functional 
genes). Recombination between adjacent diversity genes results in a recombination span of 1. 	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trend toward increased usage of downstream D genes in the 3′ D position of V(DD)J 
recombinants (p=0.2089). 
I next determined whether or not there was a preference for D-D recombination 
events between D genes located close to each other in the genomic locus. For each V(DD)J 
recombination, we determined a recombination span, calculated by subtracting the position 
number of the 5′ D gene from the position of the 3′ D gene. Recombination between 
adjacent D genes resulted in a recombination span of 1, while recombination between the 
first and last (27th) diversity genes resulted in a recombination span of 26. We observed a 
strong trend toward decreased use of the most distant pairings (Figure 21D; p=0.0568). 
Notably, although there was a global trend toward decreased pairings of distant diversity 
genes, the most frequently observed recombination span was 17, of which there were 
several D-D combinations accounting for over 10% of all V(DD)J recombinants. 
 
Skewed germline gene usage in 5′ D and 3′ D positions was likely the result of diversity 
gene orientation in the genomic locus.  
Understanding that the frequency of diversity gene use in the 5′ D position of V(DD)J 
recombinants depended on location in the genomic locus (Figure 21B), we investigated 
whether or not orientation of the genomic locus was likely to be the cause of the skewed 
diversity gene usage seen in 5′ D and 3′ D positions of V(DD)J recombinants, or whether 
other genetic or mechanistic factors were the dominant force behind the skewed diversity 
gene repertoire.  
At the 5′ D position, the complete lack of D7 family use was readily explained by the 
location of the only D7 family member, D7-27, at the 3′ end of the genomic locus: in-order 
V(DD)J rearrangements with D7-27 in the 5′ D position are not possible. The increase in D2 
family use at the 5′ D position also was likely attributable to genomic orientation. The most 
commonly used D2 gene member in the naive repertoire, D2-2, accounted for over half of 
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D2 family use in the naïve repertoire and is located one position from the 5′ end of the 
genomic locus. In addition, three of the four D2 family members, accounting for over 80% of 
D2 family use in the naive repertoire, were found in the 15 (of 27) most upstream positions 
of the genomic locus. Much like the increase in D2 family usage, the decrease in D1 family 
likely was due to the extreme downstream position of the most commonly used D1 family 
member, D1-26, which accounted for over 50% of D1 family usage in the naive repertoire. 
Finally, the trend toward increased D5 family frequency was possibly due to the positioning 
of the two most common D5 gene members, used in over 75% of D5 family use in the naïve 
repertoire, in the 5′ half of the genomic locus. 
The increase in D7 family usage in 3′ D positions likely was attributable to the fact 
that D7-27, the only D7 family member, is positioned at the furthest 3′ position of the 
genomic locus, allowing for in-order V(DD)J recombination with every other diversity gene. 
Alternatively, the decreased use of D2 family use in 3′ D positions was possibly explained by 
the fact that the most commonly used D2 family member, D2-2, is positioned such that only 
one possible V(DD)J recombination exists with D2-2 in the 3′ D position. 
 
Frequency of direct VH-JH recombinants is similar in naïve and memory subsets 
Since the occurrence of recombinants with multiple D gene suggested that non-
classical events are tolerated at some level during V(D)J recombination, I considered 
whether an alternate mechanism occurs in which a D gene is not incorporated. Naïve, IgM 
memory and IgG memory subsets were examined for the presence of recombinants that did 
not contain a D gene. These putative VH-JH recombinants were defined as sequences that 
contained an identifiable VH gene, an identifiable JH gene, but no identifiable D gene. The 
frequency of putative VH-JH recombinants did not differ statistically in naïve, IgM memory or 
IgG memory subsets (Figure 22A). This finding was in contrast to V(DD)J recombinants, 
where the frequency of V(DD)J recombinants was reduced in both memory cell subsets. 
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The variable gene family and joining gene use in 
putative VH-JH recombinants did not differ 
significantly from germline usage in the total 
repertoire (data not shown). 
 
N-addition length in putative VH-JH recombinants 
was lower than in conventional VHDH and DHJH 
regions but is similar to VL-JL N-addition length 
The nucleotide length of all junctions in 
putative VH-JH recombinants was examined and 
compared to the N-addition length for the VHDH 
and DHJH recombination sites in the total naïve 
repertoire (Figure 22B). The N-addition region at 
the VJ junction of potential VH-JH recombinants 
was significantly shorter than at the VHDH 
(p<0.0001) or the DHJH (p<0.0001) recombination 
sites in the total naïve repertoire. Interestingly 
however, the mean length of N-addition regions in 
VH-JH junctions (3.01 nt) was very similar to the 
corresponding junction in light chains (3.69 nt), 
 
Figure 22. The junctional regions of putative direct VH-JH recombinants were GC-rich and were similar to 
VL-JL recombinants in length. (A) Frequency of putative direct VH-JH recombinants in peripheral blood B cell 
subsets. (B) N-addition length for the VD and DJ junction in the total naïve repertoire and of VJ junctions in 
putative VJ recombinants. The mean N-addition length for each of four healthy individuals ± SEM is shown for 
each recombination site. The mean N-addition length at the VJ recombination site for all light chain antibody 
sequences in the IgBLAST database is also shown. (C) Histogram showing the frequency of N-addition length (in 
nucleotides) as a percentage of the putative direct VH-JH recombinant repertoire. (D) GC content for the N-
addition (N) or diversity gene (D) regions of the total naïve repertoire or of the VJ junction in putative VJ 
recombinants. The mean GC content for four healthy individuals ± SEM is shown for each recombination site. 
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which are encoded only by V and J segments. A histogram showing the length of the 
putative N-addition regions in all VH-JH recombinants (Figure 22C) revealed that very short 
N-addition lengths are highly preferred in VH-JH junctions, with nearly 9% of all putative VH-JH 
recombinants containing no N-addition and only a single sequence (0.03%) containing an N-
addition region longer than 10 nucleotides.  
 
GC content of putative VH-JH junctions resembled that in N-addition regions but differed from 
that in D gene regions 
The GC content of the VJ junction region in putative VH-JH recombinants was 
determined, as well as the GC content for N-addition and diversity gene regions in the entire 
conventional naïve repertoire (Figure 22D). The VJ junction regions in putative VH-JH 
recombinants contained GC content that was consistent with that in N-addition regions but, 
in contrast, was significantly higher than that in D gene regions (p=0.0004). Producing 
putative VH-JH recombinants by trimming of D genes would require degrading the ends of D 
gene segments in a non-random manner, consistently leaving behind D gene remnants that 
contain GC content significantly different from the D gene repertoire as a whole. Thus, it is 
likely that these recombinants are generated by direct VH-JH recombination. 
 
Identical matching of pentamers from the 3′ end of variable gene segments revealed VH 
replacement frequency 
Since coincident N-addition matches to the relatively short pentamer sequences in 
the panel would be expected to artificially inflate the VH gene replacement estimate, I 
examined both the N1 and N2 regions for identical matches to the pentamer panel. N2 
corresponds to the N-addition region between the diversity and joining genes and where VH 
replacement does not occur, and serves as a control to define the expected frequency of 
random N-addition matches to the pentamer panel. To eliminate the possibility of somatic 
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mutations altering pentamer sequences and 
producing either false positive or false 
negative results, I initially examined only 
sequences from the naïve B cell subset. I 
found that a sequence in the pentamer 
panel matched to a sequence in an N2 
region (presumably randomly) in 5.1% of 
sequences, which is much higher than in 
previous studies (Zhang et al., 2003). The 
frequency of identical N1 region matches to 
a sequence in the pentamer panel was 
6.5% (Figure 23A). The increased 
occurrence of pentamer matches in the N1 
region was highly significant (p=0.0048), 
and the difference of means suggests the 
frequency of VH replacement events to be 
≥1.43% (95% CI of 0.8-2.0%). This frequency 
is somewhat lower than previous estimates, 
which were not limited to analysis of 
sequences from naïve B cell subsets.  
To determine whether circulating 
memory B cells express sequences with an 
increased frequency of VH replacement, we pooled the IgM and IgG memory B cell subset 
sequences and performed the same analysis on the entire memory subset (Figure 23A). 
This analysis revealed a frequency of matches in the N1 region (4.9%) that was similar to 
the frequency observed in the naïve subset, indicating that somatic hypermutation does not 
Figure 23. Frequency of VH replacement in the 
peripheral blood repertoire. Frequency of VH 
replacement events based on identical matches in 
V-D recombination region (N1) to a panel of 
pentameric nucleotide sequences representing the 
3ʹ′ end of all functional variable genes. The 
frequency of the same panel of pentameric 
sequences in the D-J recombination region (N2) 
where VH replacement does not occur was used to 
define the expected frequency of random matches, 
as a negative control. The frequency of pentameric 
matches in four healthy individuals ± SEM is shown 
for each region. (B) VH replacement frequency was 
determined for each B cell subset by subtracting the 
mean N2 pentamer match frequency from the mean 
N1 pentamer match frequency. Plotted is the 
difference in means for each donor ± SEM. 
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produce a significant number of falsely positive matches to the pentamer panel. 
Interestingly, analysis of the VH recombination frequency (defined here as the mean 
frequency of identical pentamer matches in the N1 region minus the number in the N2 
region) showed a significant increase in VH recombination frequency in the class-switched 
IgG memory subset compared to the naïve subset (p=0.02, Figure 23C). 
 
Discussion 
 
The substantial differences in each subset (naïve, IgM memory and IgG memory) of 
the human peripheral blood repertoire at the individual V(D)J recombinant level, coupled 
with the overarching similarities of the repertoires at the germline gene family level, present 
something of a paradox. These data seem to suggest the presence of a broad, global 
mechanism for repertoire regulation at the germline gene family level. While there is no 
direct evidence of such a mechanism, several recent studies indicate the presence of 
repertoire-based regulatory mechanisms in circulating B cell subsets. Despite the tendency 
of pathogen-specific antibody responses to exhibit biased germline gene repertoires 
(Weitkamp et al., 2005; Tian et al., 2008; Gorny et al., 2009), the frequency of gene family 
use in naïve and memory subsets is remarkably consistent across individuals (Tian et al., 
2007; Wu et al., 2010b). Further, alteration of this gene family homeostasis in the circulating 
B cell repertoire is associated with disease states (David et al., 1995; 1996; Zouali, 1996; 
Scamurra et al., 2000). In recent work, long-lived plasma cells were shown to contain 
significantly fewer autoreactive B cells than the circulating IgG memory subset, and this 
difference was attributed to differential repertoire regulation within the two subsets (Scheid 
et al., 2011). Thus, while no mechanism for regulation of circulating human antibody 
repertoires has been identified, mounting indirect evidence, including the data presented in 
this report, suggests the presence of such regulation. 
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Three different types of recombination events were identified in the human peripheral 
blood repertoire that appear to violate the conventional 12/23 rule of recombination: 
VH(DHDH)JH recombination, direct VH-JH recombination without any DH segment, and VH 
replacement. While the occurrence of such events has been identified previously in both in 
vitro and in vivo systems, experiments in many of these systems were designed to induce 
these events in a non-physiologic manner (Akira et al., 1987; Hesse et al., 1989; Akamatsu 
et al., 1994). Further, two of these events, V(DD)J recombination and VH replacement, may 
result in antibodies that encode exceptionally long HCDR3 loops and may point to the 
genetic origin of such antibodies.  
 I identified putative V(DD)J recombinants in the naïve B cell subset at a frequency of 
approximately one in 800 circulating cells. Previous estimates of V(DD)J frequency have 
varied widely, partly due to differing criteria for identification of putative V(DD)J 
recombinants. Several methods used previously involved low-stringency filters that identified 
putative D genes using as few as four homologous nucleotides. When using such a short 
homology region to identify D-D fusion events, it is likely that many of the identified D-D 
fusions were false attributions. The presence of false positives in the identified V(DD)J 
repertoire could dilute or counteract genetic trends in the true V(DD)J population, so limiting 
falsely positive results was of critical importance. The stringent approach used in this study, 
while limiting false positives, also likely underestimated to some degree the actual frequency 
of cells that express antibodies encoded by DNAs derived from V(DD)J recombination. 
Thus, the V(DD)J frequency estimate produced in this study describes the minimum 
expected frequency of such events in the human peripheral blood repertoire. This estimate, 
while likely an underestimate of V(DD)J recombinant frequency, is approximately 20-fold 
lower than the frequency of long HCDR3s in the human peripheral blood antibody repertoire 
(Briney et al., 2012a), making it unlikely that V(DD)J recombination is the primary 
mechanism responsible for the generation of long HCDR3s.  
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To further show that the sequences in putative V(DD)J recombinants identified in this 
study were generated by true D-D fusion and not alignment of coincidental N-addition 
mediated sequences, I closely analyzed the nucleic acid characteristics of sequence regions 
within putative V(DD)J recombinants and determined that it is highly unlikely that N-addition 
mimicry was the primary cause of these putative V(DD)J recombinants. Analysis of N-
addition length, GC-content and orientation of the 5ʹ′ and 3ʹ′ D gene segments in V(DD)J 
recombinants all suggest that the N-addition mimicry mechanism is unlikely to account for 
these sequences. Random addition of nucleotides that coincidentally match germline D 
genes while satisfying all of the conditions identified above would require an extraordinarily 
unlikely set of events.  
The  frequency and genetic composition of direct VH-JH recombination events in the 
human peripheral blood repertoire was also determined. While the possibility that some of 
these sequences are the product of extensive trimming of D genes cannot definitively be 
excluded, analysis of the nucleic acid characteristics of the junctional region in putative VH-
JH recombinants revealed that it is highly unlikely that D gene trimming was the primary 
source of these recombinants. In contrast to V(DD)J recombinants, the frequency of putative 
VH-JH recombinants, which encode much shorter CDR3 loops than the putative V(DD)J 
recombinants, was similar in naïve and memory cell subsets. This finding raises an 
interesting question: why do clones with the very short HCDR3 loops generated by putative 
direct VH-JH recombination transition from naïve to memory at a much higher frequency than 
clones that possess the longer CDR3 loops that are encoded in V(DD)J recombinants? B 
cells of the IgM memory and IgG memory subsets have significantly shorter mean CDR3 
lengths than the total naïve subset (Tian et al., 2007). It is possible that flat or convex 
epitopes, which would likely not pair well with antibodies containing long, protruding 
HCDR3s, are targeted more frequently by naïve B cells, resulting in an increased fraction of 
short HCDR3s in the memory repertoire.  
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VH replacement, a process of secondary recombination between variable genes and 
previously completed V(D)J recombined genes, has been shown in humans and animal 
model systems to facilitate the rescue of cells with non-functional or autoreactive primary 
recombinations (Zhang et al., 2004; Lutz et al., 2006). Published frequency of VH 
replacement in the peripheral blood antibody repertoire has varied widely (Zhang et al., 
2003; Koralov et al., 2006; Watson et al., 2006). I found matches to the pentamer panel in 
the N1 region at similar frequencies to those reported by Zhang, et al. There was far more 
coincidental matching of the pentamer panel in the N2 region than was noted in that study, 
however, indicating that the true VH replacement frequency is substantially lower than 
previously thought. Although the frequency of VH replacement is similar to the frequency of 
long HCDR3s, VH replacement typically only adds 5-6 nucleotides to the overall HCDR3 
length. Thus, VH replacement alone is likely not sufficient to convert an HCDR3 of normal 
length (approximately 15 amino acids) into an HCDR3 of extreme length like that of PG9 or 
PG16 (30 amino acids). 
While the frequency of VH replacement reported here is lower than that of previous 
work, the data presented here constitutes the first report of an increase in VH replacement in 
memory cell subsets when compared to cells in the naïve subset. This surprising discovery 
suggests either that B cells containing antibodies generated by VH replacement transition to 
the memory subset more frequently that B cells that have not undergone VH replacement, or 
that VH replacement can occur in mature B cell populations, raising the possibility of antigen-
driven VH recombination in humans. Other studies have shown that stimulation of B cells 
with IL-4 or IL-7 and CD40 can induce RAG expression, that RAG proteins are expressed in 
germinal center B cells (Han et al., 1997; Papavasiliou et al., 1997) and that secondary 
recombinations occur in mouse germinal centers (Wang and Diamond, 2008). Thus, it is 
feasible that there is a window for VH replacement in mature human B cells at or near the 
time of stimulation.
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CHAPTER IV 
 
GENETIC FEATURES OF BROADLY NEUTRALIZING HIV ANTIBODIES ARE PRESENT 
IN THE PERIPHERAL BLOOD REPERTOIRE OF UNINFECTED INDIVIDUALS 
 
Introduction 
 
Antibodies with long HCDR3s 
Antibodies containing long heavy chain complementarity determining region 3 
(HCDR3) loops have been shown to efficiently neutralize a wide variety of pathogens, 
including HIV, malaria, and African trypanosomes (Stijlemans et al., 2004; Burton et al., 
2005b; Henderson et al., 2007). In some cases, the unique feature of long HCDR3 
antibodies is that the extended loop structure facilitates interaction with epitopes that are 
otherwise occult because of extensive glycosylation or location in recessed structures on the 
pathogen surface.  
For HIV, several of the most broad and potently neutralizing antibodies have 
extremely long HCDR3 loops. Two exceptionally broad and potent anti-HIV antibodies, PG9 
and PG16, encode among the longest human antigen-specific antibodies described to date 
and form secondary structure through the use of a complex hydrogen bonding network in 
the HCDR3 (Walker et al., 2009; Pancera et al., 2010). These antibodies target a currently 
undefined quaternary epitope and preferentially bind cell surface expressed trimeric 
envelope protein (Doores and Burton, 2010; Pejchal et al., 2010). In addition to long 
HCDR3s, both antibodies contain sulfated tyrosine residues within the HCDR3, a post-
translational modification that has only recently been observed in antibody combining sites 
(Walker et al., 2009). Two additional HIV antibodies, designated 2.5b and 2909, target a 
	   62 
similar quaternary epitope and contain long HCDR3s, but are able to neutralize only a very 
limited panel of virus isolates (Changela et al., 2011; Spurrier et al., 2011). A panel of 
recently described antibodies, PGT141-PGT145, are purported to target the same 
quaternary epitope as PG9 and PG16, have a similar strong preference for membrane-
bound, trimeric envelope, and encode HCDR3s that are even longer than the exceptionally 
long HCDR3s seen in PG9 and PG16 (Walker et al., 2011). The broadly neutralizing HIV 
antibody b12 contains a long HCDR3 and is able to neutralize by targeting the conserved 
CD4 binding site (Burton et al., 1991; Barbas et al., 1993; Burton et al., 1994). The b12 
antibody uses only heavy chain interactions at the antigen binding interface, and passive 
administration of b12 has been shown to be protective against low-dose repeated challenge 
in macaques (Saphire et al., 2001; Hessell et al., 2009). Two other broadly neutralizing 
antibodies with long HCDR3s, 4E10 and 2F5, target a conserved membrane-proximal 
region and have been shown to protect against mucosal SHIV challenge alone and in 
combination with the anti-HIV antibody 2G12 (Mascola et al., 1999; 2000; Stiegler et al., 
2001; Hessell et al., 2010), and the long HCDR3 of 2F5 is critical to the neutralizing ability of 
2F5 (Zwick et al., 2004a). Antibody 447-52D contains a long HCDR3 loop and is able to 
neutralize a broad range of clade B HIV-1 isolates by targeting a conserved epitope on the 
V3 loop of gp120 (Stanfield et al., 2004; Jiang et al., 2010). Finally, the neutralizing antibody 
17b targets the HIV co-receptor binding site and facilitates neutralization by preventing co-
receptor binding and reducing affinity for the primary receptor, cluster of differentiation 4 
(CD4) (Kwong et al., 1998). Thus, antibodies containing long HCDR3s comprise a sizeable 
fraction of the neutralizing HIV antibodies described to date, including many of the most 
broad and potently neutralizing antibodies. 
Although induction of such long HCDR3 antibodies is likely to be critical to the design 
of an effective HIV vaccine strategy, it is still unclear how to induce such antibodies. 
Previous work has speculated as to a potential mechanism for inducing such antibodies by 
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vaccination (Pejchal et al., 2009; Pancera et al., 2010). It is known that the affinity 
maturation process is associated with codon-length insertion events that are likely caused 
by the somatic hypermutation machinery (Wilson et al., 1998a; 1998b; Reason and Zhou, 
2006). It is thought, then, that repeated rounds of affinity maturation, resulting in multiple 
short insertion events within the HCDR3, could gradually lengthen HCDR3 loops in the 
affinity matured antibodies. This observation fits well with the known kinetics of broadly 
neutralizing antibody generation during HIV infection: potently neutralizing HIV antibodies 
are produced later than is common in other viral infections (Richman et al., 2003; Wei et al., 
2003), suggesting that many rounds of affinity maturation may be necessary to develop 
broad and potent neutralizing capacity. 
 It is also possible that long HCDR3 loops are not generated primarily through the 
affinity maturation process, however, and are instead primarily created during the 
recombination process through the introduction of extensive numbers of N- and P-insertions 
and the selective use of optimal germline gene segments. If the primary source of long 
HCDR3 antibodies in the peripheral blood is not affinity maturation, the process of inducing 
an antibody response containing antibodies with long HCDR3s would consist of exhaustive 
sampling of the repertoire to select those B cells encoding what are, presumably, rare 
antibodies (Pancera et al., 2010; Pejchal et al., 2010). While it has previously been shown 
that antibodies containing long HCDR3s are present in immature B cell populations in both 
man (Ivanov et al., 2005) and mouse (Schelonka et al., 2008; Vale et al., 2010) as well as in 
human perinatal liver (Schroeder and Wang, 1990), it is unclear how frequently these 
antibodies are able to successfully navigate the autoreactivity screening process and enter 
the mature B cell population. Extensive work has been done in characterizing short and long 
HCDR3s in mice (Ippolito et al., 2006; Schelonka et al., 2007; Schroeder et al., 2010), but 
much of the work was done model systems under non-physiologic conditions. An 
examination of hundreds of thousands of circulating human antibody sequences has 
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identified an upper limit to the number of unique HCDR3s in a single individual (Arnaout et 
al., 2011). The upper bound, 3 to 9 million unique HCDR3s per individual, is much lower 
than previously estimated, but this study did not describe the length distribution of these 
HCDR3s. It has been shown that many B cells encoding HCDR3s of extreme length are 
eliminated before reaching the periphery (Ivanov et al., 2005), likely because antibodies with 
long HCDR3s tend to have autoreactive properties (Crouzier et al., 1995; Aguilera et al., 
2001; Wardemann et al., 2003; Haynes et al., 2005). Detailed study and genetic 
characterization of the long HCDR3 antibody population in human peripheral blood has 
been limited by the rarity of such sequences. In this study, I examined expressed antibody 
sequences from four healthy donors and determined that antibodies containing long 
HCDR3s are more common in the naïve subset than in memory, indicating that affinity 
maturation is not the primary source of such antibodies. Further, extensive genetic 
characterization identified several conserved sequence elements in the long HCDR3 
peripheral blood antibody population. Thus, human peripheral blood antibodies containing 
long HCDR3s are not generated primarily through repetitive rounds of affinity maturation, 
but are typically formed at the time of the original recombination. 
 
Antibodies with somatic hypermutation-associated insertions and deletions 
 The somatic hypermutation (SHM) process typically results in single point mutations, 
but occasionally produces insertions or deletions of varying length (citations). Several 
antibodies have recently been described for which somatic hypermutation-associated 
insertions and deletions (SHA indels) are critical to proper antigen binding. For HIV, there 
are several bnAbs that require SHA indels for potent neutralization. In the case of VRC01, a 
bnAb that targets the CD4bs, a six nucleotide deletion in the light chain CDR1 (LCDR1) 
reduces the size of the LCDR1 and removes steric clashes with the target antigen (Wu et 
al., 2010a). When the deletion is restored, binding and neutralization are severely reduced.  
	   65 
 As with long HCDR3-encoding antibodies, much effort is being directed toward the 
design of immunogens that efficiently elicit bnAbs. In the case of bnAbs that require SHA 
indels for appropriate function, it is critical to know whether antibodies encoding these SHA 
indels must be induced by the vaccine or whether they are already present in the HIV-
uninfected antibody repertoire. The latter prospect is especially appealing, since selection of 
antibodies containing pre-existing SHA indels is thought to be much simpler that designing 
immunogens that specifically elicit such SHA indels. Thus, examination of the HIV-
uninfected peripheral blood repertoire and characterizing the frequency and distribution of 
SHA indels is an important first step toward the design of immunogens that successfully 
induce a broadly neutralizing HIV response. 
 
The Genetic Origin of Antibodies Encoding Long HCDR3s 
 
Increased HCDR3 length was not associated with an increased number of somatic 
mutations or insertions.  
Three major subsets of B cells in the peripheral blood were considered:  naïve B 
cells, which are antigen inexperienced and lack somatic mutations or class-switching; IgM 
memory B cells, which express the surface memory marker CD27 and show evidence of 
somatic hypermutation but not class-switching; and IgG memory cells, which express CD27 
and have undergone both somatic hypermutation and class-switching. Naïve, IgM memory 
and IgG memory B cells were separately isolated from four healthy individuals (hereafter, 
designated Group 1) using flow cytometric sorting and subjected the transcribed antibody 
heavy chain genes from those cells to high throughput sequencing. After selecting only non-
redundant, high-quality antibody sequences, a total of 294,232 naïve cell sequences, 
161,313 IgM memory cell sequences and 94,841 IgG memory cell sequences were obtained 
from Group 1 donors. I also subjected the transcribed peripheral blood heavy chain antibody 
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genes of three additional 
healthy donors 
(hereafter, designated 
Group 2) and four HIV-
infected donors to high 
throughput sequencing. 
The B cells from these 
additional donors were 
not sorted by B cell 
subset prior to 
sequencing, but instead 
represent a sampling of 
the total peripheral 
blood B cell repertoire 
from each donor. 
 Peripheral blood 
antibody sequences 
Figure 24. Increased HCDR3 length does not correlate with affinity maturation events. (A) Peripheral 
blood antibody sequences were grouped by mutation frequency and the percent of sequences in each group 
that contained codon-length (non-frameshift) insertions was calculated for each donor. All values for healthy 
donors from Group 1 (n=4) and Group 2 (n=3) are shown in the left panel, with the mean percentage ± SEM 
shown for each mutation value. In the right panel, sequences from Group 1 healthy donors were segregated 
by B cell subset, and the best-fit linear regression for each subset is shown. (B) Peripheral blood antibody 
sequences were grouped by HCDR3 length (in amino acids) and the mean number of mutations for each 
HCDR3 length group was calculated for each donor. As in Figure 1A, the left panel shows the mean ± SEM for 
all donors in Group 1 and Group 2. The right panel shows the best-fit linear regression of each B cell subset 
for Group 1 donors. The percent of sequences within each HCDR3 length group containing non-frameshift 
insertions also was calculated. In the left panel, the mean percentage ± SEM for all donors in Group 1 and 
Group 2 is shown. In the right panel, the best-fit linear regression of each B cell subset is shown for Group 1 
donors. (C) Peripheral blood antibody sequences from Group 1 healthy donors were grouped by donor into 
naïve and memory subsets and the percent of sequences containing long HCDR3s (≥24 amino acids in length, 
or two standard deviations above the mean HCDR3 length). The percentages for each donor are shown, with 
the mean ± SEM. (D) The donor groups from Figure 1C were analyzed for the frequency of very long HCDR3s 
(≥28 amino acids in length, i.e., three standard deviations above the mean HCDR3 length). The percentages 
for each donor are shown, with the mean ± SEM. The p values were determined using a one-way ANOVA. All 
statistically significant differences are indicated. * = p<0.05, ** = p<0.01, *** = p<0.001 
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from Group 1 and Group 2 healthy donors were grouped by mutation frequency, and the 
fraction of sequences containing insertions was determined for each group (Figure 24A, left 
panel). In agreement with previously published data (Wilson et al., 1998a), I observed a 
strong positive correlation between number of mutations and insertion frequency (r2=0.77, 
p<0.0001). Insertions were present only in a minority of the most highly mutated sequences, 
however, suggesting either that the somatic hypermutation process is inefficient at 
introducing insertions in a functional reading frame or that antibodies seldom are able to 
tolerate genetic insertions while retaining functionality. When separately analyzing each of 
the B cell subsets from Group 1 healthy donors, I observed that the correlation between 
mutations and insertions also was found for each of the memory B cell subsets (Figure 24A, 
right panel). 
I next grouped the sequences by HCDR3 length and determined the mean number 
of mutations and insertion frequency for each HCDR3 length group (Figure 24B, left panels). 
Interestingly, HCDR3 length was negatively correlated with both mutation frequency 
(r2=0.64, p<0.0001) and insertion frequency (r2=0.13, p<0.0001), suggesting that genetic 
processes that accomplish somatic hypermutation typically do not alter HCDR3 length. A 
similar trend was seen in each of the Group 1 healthy donor B cell subsets (Figure 24B, 
right panels). It has been shown previously that the mean HCDR3 length in circulating 
memory B cell subsets is shorter than in the naïve B cell subset by approximately a single 
amino acid (Wu et al., 2010b). Analyzing the mean HCDR3 length, however, does not allow 
determination of whether there is a broadly-distributed, overall shortening of the entire 
HCDR3 repertoire (perhaps caused by somatic hypermuation-induced deletions in the 
HCDR3 that reduce the length of both long and short HCDR3s) or whether the lower mean 
HCDR3 length in memory is predominantly due to a strong preference against long HCDR3s 
in the memory subset. I examined the antibody sequences from naïve, IgM memory, and 
IgG memory B cell subsets from Group 1 healthy donors for presence of long HCDR3s 
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(defined here as HCDR3s ≥ 24 amino acids, which corresponds to 2 SD above the mean 
HCDR3 length) and for very long HCDR3s (defined here as HCDR3s ≥ 28 amino acids, 
which corresponds to 3 SD above the mean HCDR3 length). The naïve population 
contained a significantly higher fraction of long HCDR3s (3.5%, Figure 24C) than both the 
IgM memory subset (0.74%, p=0.0003) and the IgG memory subset (1.9%, p=0.014). The 
naïve subset also contained a significantly higher fraction of very long HCDR3s (0.43%, 
Figure 24D) than either the IgM memory subset (0.06%, p=0.001) or the IgG memory subset 
(0.19%, p=0.038). Interestingly, the IgM memory subset showed a significantly reduced 
frequency of long HCDR3s when compared with the IgG memory subset (p=0.0056), which 
supports emerging data that the IgM memory subset does not function primarily as a 
transition state in progression from the naïve to IgG memory repertoire (Wu et al., 2010b). In 
summary, introduction of point mutations and insertions during somatic hypermutation had 
little effect on HCDR3 length, and I noted the somewhat surprising presence of a large 
population of long HCDR3s in the naïve repertoire. These data suggested that long 
HCDR3s are not built primarily through repeated rounds of affinity maturation using genetic 
insertions, but are present in the naïve repertoire before B cells begin the affinity maturation 
process. 
 
Antibody sequences encoding long or very long HCDR3s display skewed germline gene 
usage.  
With the understanding that long HCDR3s are not produced primarily by the affinity 
maturation process, I examined the antibody repertoire for evidence of recombination events 
that correlate with HCDR3 length. First, I grouped the peripheral blood antibody sequences 
from each Group 1 and Group 2 healthy donor by three criteria: (1) all HCDR3s, which 
included all antibodies containing any HCDR3 length; (2) long HCDR3s, which  
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Figure 25. Skewed germline gene usage in antibodies containing long or very long HCDR3s. 
Peripheral blood antibody sequences from Group 1 (n=4) and Group 2 (n=3) healthy donors were 
assembled into the following three groups by HCDR3 length: (1) all HCDR3s, which contains all 
sequences of any HCDR3 length; (2) long HCDR3s, which contains only sequences with a HCDR3 
length ≥ 24 amino acids; and (3) very long HCDR3s, which contains only sequences with a HCDR3 
length ≥ 28 amino acids. The frequency of each germline variable gene family, diversity gene family, 
and joining gene was determined for each HCDR3 length group. The mean frequency ± SEM is shown. 
All HCDR3 lengths were calculated using the IMGT numbering system. The p values were determined 
using a two-way ANOVA with Bonferroni post-tests. All statistically significant differences are indicated. 
* = p<0.05, ** = p<0.01, *** = p<0.001 
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included only sequences with HCDR3 lengths ≥ 24 amino acids long; and (3) very long 
HCDR3s, which included only sequences with HCDR3 lengths ≥ 28 amino acids long.  
I analyzed the germline V, D and J gene segment use in each of the three sequence 
groups (Figure 25). The most remarkable finding noted was the strong association of two 
particular D gene families and one J gene segment with longer HCDR3s. Use of D gene 
families D2 and D3 was increased in long HCDR3s (both D2 and D3: p<0.001) and very 
long HCDR3s (both D2 and D3: p<0.001). A significant decrease in use of D gene family D6 
was seen in long and very long HCDR3s (p<0.01), and a decrease in D1 gene family use 
was seen in long HCDR3s (p<0.01). Use of J gene JH6 was increased markedly in both long 
(p<0.001) and very long HCDR3s (p<0.001), while joining gene JH4 use was decreased in 
long (p<0.001) and very long HCDR3s (p<0.001). This was not surprising, considering that 
JH6 is the longest JH gene segment and JH4 is the shortest. Interestingly, however, use of 
JH1 and JH2, which are two amino acids longer than JH4, was not increased significantly in 
long or very long HCDR3 groups. We also noted some variation in VH gene usage. Use of 
variable gene family VH1 was increased in the long HCDR3 (p<0.05) and very long HCDR3 
(p<0.05) groups compared to the group with all HCDR3 lengths (p<0.05). VH3 family use 
was decreased in long HCDR3s (p<0.05) but not in the very long HCDR3 group. Separate 
analysis of the individual B cell subsets in Group 1 donors indicated that the trends 
observed for the total repertoire were largely mirrored in each subset repertoire. 
Deeper analysis of individual D gene use (as opposed to analysis of the D gene 
families shown in Figure 2) revealed that the increase in D2 and D3 gene families is driven 
almost completely by increased use of just three of the nine D2 and D3 gene family 
members: D2-2, D2-15 and D3-3 (Figure 27A). Separate analysis of the frequency of the 
three D genes that were increased in the total repertoire in each B cell subset (Figure 27B-
D) showed similar trends, although the reduced sample size of each subset, as well as the  
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infrequency of long HCDR3s in both memory subsets, resulted in trends that were less 
robust. The pattern of diversity gene use in long HCDR3s was somewhat surprising, since 
D3-16, which is not increased in long or very long HCDR3s, is two amino acids longer than 
any of the three preferred D genes. Further, four additional D genes, D2-8, D3-9, D3-10 and 
D3-22 are the same length as the three preferred genes, but are not significantly more 
common in long or very long HCDR3s than in the total repertoire. Thus, while the D2 and D3 
gene families encode the longest D genes found in the repertoire, the increased frequency 
of only a select few of the diversity genes in these families indicates that length is not the 
only factor driving the increased frequency of these D gene segments in long and very long 
HCDR3 repertoires. 
 
Increased HCDR3 length correlated with genetic features associated with recombination.  
I next grouped all of the peripheral blood antibody sequences from Group 1 and 
Group 2 healthy donors by HCDR3 length and determined the average N-addition length 
and P-addition length (Figure 26A, left panels) for each HCDR3 length group. Both features 
showed positive correlations, with N-addition increasing exponentially (r2=0.96) and 
Figure 26. (previous page) Long HCDR3s correlate with N-addition, P-addition and germline gene 
usage. For all figure sections, the leftmost panel corresponds to peripheral blood antibody sequences from 
Group 1 (n=4) and Group 2 (n=3) healthy donors. The middle panel corresponds to antibody sequences from 
Group 1 donors, segregated by B cell subset. The rightmost panel corresponds to peripheral blood antibody 
sequences from HIV-infected donors (n=4). (A) Peripheral blood antibody sequences were grouped by 
HCDR3 length (in amino acids) and the average N-addition length and P-addition length (both in nucleotides) 
was calculated for each HCDR3 length group. The mean length ± SEM is shown. Regression analysis of N-
addition length produced a non-linear, exponential curve of best fit. Regression analysis of P-addition length 
produced a linear best fit. (B) Peripheral blood antibody sequences were grouped by HCDR3 length and the 
frequency of sequences encoding either diversity gene family 2 (D2) or diversity gene family 3 (D3) was 
calculated for each HCDR3 length group. The mean frequency of D2/D3 gene family use ± SEM for each 
HCDR3 length group is shown. Regression analysis produced a non-linear, sigmoidal curve of best fit. (C) 
Peripheral blood antibody sequences were grouped by HCDR3 length and the frequency of sequences 
encoding joining gene 6 (JH6) was calculated for each HCDR3 length group. The mean frequency of D2/D3 
gene family use ± SEM for each HCDR3 length group is shown. Regression analysis produced a non-linear, 
sigmoidal curve of best fit. (D) The frequency of sequences encoding both the JH6 germline gene and D2/D3 
germline gene family members was determined for each HCDR3 length group. The mean frequency of 
JH6/D2/D3 gene family use ± SEM for each HCDR3 length group is shown. Non-linear regression analysis 
produced a sigmoidal curve of best fit. 	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Figure 27. Frequency of D gene use in long and very long HCDR3s. Antibody sequences from Group 1 healthy donors (n=4) were 
assembled into the following three groups by HCDR3 length: (1) all HCDR3s, which contains all sequences of any HCDR3 length; (2) 
long HCDR3s, which contains only sequences with a HCDR3 length ≥ 24 amino acids (at least two standard deviations above the mean 
HCDR3 length for the entire repertoire); or (3) very long HCDR3s, which contains only sequences with a HCDR3 length ≥ 28 amino 
acids (at least three standard deviations above the mean). The frequency of diversity gene use in each of the three groups was 
determined for Group 1 healthy donor sequences (A). For the diversity genes that showed significant increases in (A), frequency was 
calculated for the naive (B), IgM memory (C), and IgG memory (D) subsets from the same Group 1 donors. The mean frequency ± SEM 
is shown. All HCDR3 lengths were calculated using the IMGT numbering system. The p values were determined using a two-way 
ANOVA with Bonferroni post tests. All statistically significant differences are indicated. * = p<0.05, ** = p<0.01, ***=p<0.001 
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P-addition increasing linearly (r2=0.35, p<0.0001) with increasing HCDR3 length. Similar 
correlations were seen when analyzing individual B cell subsets from Group 1 healthy 
donors (Figure 26A, middle panels) and peripheral blood antibody sequences from HIV-
infected donors (Figure 26A, right panels).  
Following the observation that germline gene usage was skewed in long HCDR3s 
(Figure 25), I examined the use of D2/D3 (i.e., D2 or D3) family genes as a combined group 
more closely. We first examined peripheral blood antibody sequences from Group 1 and 
Group 2 healthy donors (Figure 26B, left panel), and non-linear regression analysis revealed 
a sigmoidal correlation between D2/D3 gene use (r2=0.80) and HCDR3 length, with 
combined D2/D3 gene use exceeding 80% in the longest HCDR3s. The increased use of 
D2/D3 genes was not surprising, as the D2 and D3 nucleotide sequences are the longest in 
diversity gene families. This correlation also was seen when analyzing the individual subsets 
of Group 1 healthy donors (Figure 26B, middle panel) and peripheral blood antibody 
sequences from HIV-infected donors (Figure 26B, right panel; r2=0.61). Analysis of JH6 gene 
use in the peripheral blood antibody repertoire of Group 1 and Group 2 healthy donors 
(Figure 26B, left panel) revealed a sigmoidal correlation between JH6 gene use and 
increasing HCDR3 length (r2=0.87). JH6 was used in less than 10% of the shortest HCDR3s, 
but was present in over 75% of the longest HCDR3s. I observed a similar correlation when 
analyzing the individual subsets of Group 1 healthy donors (Figure 26C, middle panel) and 
peripheral blood antibody sequences from HIV-infected donors (Figure 26C, right panel; 
r2=0.83). The observed preference for JH6 was expected, as JH6 is by far the longest J gene, 
adding as many as five more codons to the HCDR3 than the shortest J genes. I also 
examined the peripheral blood repertoire of Group 1 and Group 2 healthy donors to 
determine the frequency of sequences that use both JH6 and D2/D3 genes (Figure 26D, left 
panel) and found a strong sigmoidal correlation between combined JH6 and D2/D3 use 
(r2=0.81). While combined JH6 and D2/D3 use was unusual in the shortest HCDR3s (3.0%), 
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D2-JH6 and D3-JH6 encoded antibodies 
comprised the majority of the repertoire of 
the longest of HCDR3s (58.8%). The trend 
toward increased use of JH6 and D2/D3 also 
was seen in individual subsets of Group 1 
healthy donors (Figure 26D, middle panel) 
and in HIV-infected donors (Figure 26D, 
right panel; r2=0.81). Further analysis of 
Group 1 and Group 2 healthy donors 
revealed a correlation between HCDR3 
length and use of JH6 in sequences that do 
not incorporate D2/D3 (Figure 28A) and 
between HCDR3 length and in use of D2/D3 
in sequences that do not incorporate JH6 
(Figure 28A), but the positive correlation 
only extended to HCDR3 lengths of 
approximately 20 amino acids. This finding 
suggested that while use of one germline 
gene (either JH6 or D2/D3) is sufficient to allow generation of relatively long HCDR3s, both 
germline genes are required to generate the longest HCDR3s.  
 
Diversity gene reading frame 2 is used preferentially in long HCDR3s.  
I next analyzed the reading frame preferences in long HCDR3s. We used the 
ImMunoGeneTics (IMGT) method for calculating the D gene reading frame, which 
determines the reading frame based on the first codon of the D gene nucleotide sequence. 
The functional reading frame equivalent to IMGT reading frame 2 (RF2) has been shown to 
Figure 28. Limited preference for isolated use of 
D2/D3 or JH6 in the longest HCDR3s. Peripheral 
blood antibody sequences from Group 1 (n=4) and 
Group 2 (n=3) healthy donors were grouped by 
HCDR3 length (in amino acids) and the frequency 
of (A) sequences encoding germline genes from the 
D2 or D3 families but not JH6 or (B) sequences 
encoding JH6 but not either of the D2 or D3 
families. The mean frequency ± SEM is shown. All 
HCDR3 lengths were calculated using the IMGT 
numbering system. 
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be the most common reading frame in the overall repertoire (Ivanov et al., 2005; Ippolito et 
al., 2006; Schelonka et al., 2008; Zemlin et al., 2008; Schroeder et al., 2010), however, 
there was a significantly increased preference for RF2 in long HCDR3s in the peripheral 
blood antibody repertoire of Group 1 and Group 2 healthy donors (Figure 29A, left panel; 
p<0.001) and in HIV-infected donors (Figure 29A, right panel; p<0.05). A significant increase 
in RF2 use was also seen in very long HCDR3s in both healthy and HIV-infected donors 
(Figure 29A; p<0.001 and p<0.01, respectively). Although this reading frame is identified by 
IMGT as RF2, alternate methods of determining the reading frame, which are based on 
analysis of the amino acid sequence instead of the nucleotide sequence, produce a different 
reading frame nomenclature. The reading frame identified as RF2 by IMGT would be 
identified as RF1 using the alternate “functional” reading frame determination system. To 
keep confusion to a minimum, the IMGT nomenclature will be used for the remainder of this 
report. The increased RF2 use in long HCDR3s was unexpected because alternating the 
reading frame of the D gene should not affect the overall sequence length significantly. 
However, when analyzing the peripheral blood repertoire of Group 1 and Group 2 healthy 
donors, I discovered that the frequency of RF2 in the longest HCDR3s (Figure 29B, left 
panel; 69%) was over twice the frequency of RF2 in the shortest HCDR3s (28%). A similar 
pattern was seen in HIV-infected individuals (Figure 29B, right panel).  
I next considered whether RF2 was selected more frequently in long HCDR3s 
because use of RF2 may have allowed for more efficient in-frame recombination with the 
highly preferred JH6 gene. Examination of long HCDR3s in Group 1 and Group 2 healthy 
donors showed a similarly strong preference for RF2 (74%, r2=0.55) in the longest HCDR3s 
of recombinants that did not use the JH6 gene (Figure 29C, top left panel) than was seen in 
the total repertoire. The same trend also was seen in sequences that used JH6 (Figure 29C, 
bottom left panel; 75%, r2=0.44). A similar pattern of RF2 use in the presence or absence of 
JH6 also was seen in cells from the HIV-infected subjects (Figure 29C, right panels). Thus, 
	  	   77 
	  	   78 
the observed RF2 preference in long HCDR3s was not primarily due to the need to form in-
frame recombinations with JH6.  
Antibodies with long, hydrophobic HCDR3s often possess autoreactive properties 
(Crouzier et al., 1995; Aguilera et al., 2001; Wardemann et al., 2003; Haynes et al., 2005), 
and RF2 has been shown to be preferred in the antibody repertoire likely due to increased 
tyrosine frequency and lower hydrophobicity than other reading frames (Ivanov et al., 2002; 
Zemlin et al., 2008). Diversity genes in the D2 and D3 families are enriched for tyrosine 
residues, although the three D genes with the highest tyrosine content (D3-10, D3-16 and 
D3-22) were not among the preferred D genes (data not shown). I next analyzed the 
frequency of hydrophobic residues (Figure 29D) and the grand average of hydropathicity 
(GRAVY, Figure 29E) of each functional reading frame for the D2 and D3 families, with 
special attention paid to the three germline D genes that were found most often in long 
HCDR3s (designated by filled circles). Although the broader results validate previous data 
(namely that RF2 is much less hydrophobic than other reading frames), RF2 of the three 
preferred germline genes is not substantially less hydrophobic than RF2 of the other, non-
preferred, D2/D3 gene members. Thus, although hydrophobicity and tyrosine frequency may 
Figure 29. (previous page) Long HCDR3s preferentially use reading frames (RF) that result in reduced 
hydrophobicity. (A) Peripheral blood antibody sequences from Group 1 and Group 2 healthy donors (left 
panel) or HIV-infected donors (right panel) were assembled into three HCDR3 length groups: (1) all HCDR3s; 
(2) HCDR3s of at least 24 amino acids; and (3) HCDR3s of at least 28 amino acids. (B) The percentage of 
sequences within each HCDR3 group using reading frame 2 of the diversity gene (RF2) was calculated for 
each HCDR3 length group. Non-linear regression analysis produced a sigmoidal curve of best fit (r2=0.84). 
(C) Sequences that do not encode the joining gene JH6 (top panel) or do encode JH6 (bottom panel) were 
grouped by HCDR3 length and RF2 use within each HCDR3 length group was determined. The mean 
frequency ± SEM is shown. Non-linear regression analysis produced a sigmoidal curve of best fit. (D) The 
percentage of hydrophobic residues was calculated for each reading frame of every functional (lacking stop 
codons) diversity gene in the D2 and D3 germline gene families. The mean percentage ± SEM is shown for 
each reading frame. The RF2 hydrophobicity of the diversity genes which were shown to be increased in long 
HCDR3s are indicated by filled circles. The p values were determined using a Student’s two-tailed t-test. (E) 
The grand average of hydropathicity (GRAVY) was calculated for each functional reading frame of each D2 
and D3 gene. A positive GRAVY score indicates hydrophobicity, and a negative GRAVY score indicates 
hydrophilicity. The mean GRAVY score ± SEM is shown for each reading frame. The RF2 GRAVY scores of 
the diversity genes that were shown to be increased in long HCDR3s are indicated by filled circles. The p 
values were determined using Student’s two-tailed t-test. All statistically significant differences are indicated.  
* = p<0.05, ** = p<0.01, *** = p<0.001 	  
	  	   79 
drive the overwhelming prominence of RF2 in the normal antibody repertoire, they do not 
seem to account for the strong preference for the three highly preferred D genes in the long 
HCDR3 repertoire. 
 
Amino acid residues critical to binding and neutralization of HIV by broadly neutralizing 
antibodies PG9 and PG16 are encoded by JH6 and D3-3 germline genes.  
The broadly neutralizing HIV antibodies PG9 and PG16 contain the longest HCDR3s 
of any antigen-specific human monoclonal antibodies described to date (Walker et al., 
2009). I considered the genetic basis for development of these unusual antibodies in light of 
the information presented above on the typical origin of long HCDR3s. These clonally 
related antibodies both possess HCDR3 regions containing 30 amino acids, which is twice 
the mean HCDR3 length in the total repertoire. Remarkably, both PG9 and PG16 antibodies 
use D3-3, one of the three D genes highly preferred in long HCDR3s, and JH6. Further, both 
antibodies position the diversity gene in RF2. I performed amino acid sequence alignments 
with PG9 or PG16 and the corresponding germline D and J genes (Figure 30). Based on 
Figure 30. Amino acid residues in JH6 and RF2 of D3-3 germline gene segments are critical to binding 
and neutralization of HIV by long HCDR3-containing antibodies PG9 and PG16. The HCDR3 amino acid 
sequences of HIV-specific mAbs PG9 and PG16 are shown aligned to the amino acid sequences of germline 
D3-3 and JH6 genes. Dashes in the alignments indicate conservation with the respective PG antibody. 
Residues shown to be critical to binding or neutralization of HIV, defined as ≥10-fold decrease in either binding 
or neutralization when mutagenized are indicated by filled circles. 
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previous studies (Pejchal et al., 2010), I identified eight critical residues in these antibodies 
for which a ≥ 10-fold decrease in either binding or neutralization occurred when those single 
amino acids were mutagenized. Interestingly, six of the eight critical residues were encoded 
by the germline sequence of the D and J genes. Although two additional crucial residues 
appear to be encoded by N-addition, it is impossible to rule out the possibility that these 
residues are the consequence of a post-recombination insertion  
event. Thus, the molecular basis for development of these most broadly neutralizing 
antibodies for HIV using very long HCDR3s was not a rare occurrence of unusual mutations. 
Instead, these antibodies were derived from a typical, almost canonical, selection of a D3-3 
gene using RF2 and JH6, and much of the high affinity of these antibodies derives from 
interactions mediated by unmutated germline-encoded residues. 
 
Somatic Hypermutation-Associated Insertions and Deletions 
 
Frequency of in-frame insertions and deletions associated with somatic hypermutation.  
I separately isolated naïve, IgM memory and IgG memory B cells from four healthy 
individuals using flow cytometric sorting, extracted total RNA and performed RT-PCR to 
amplify antibody genes from those cells, and subjected the resulting amplicons to high 
throughput DNA sequencing. After selecting only high-quality, non-redundant antibody 
sequences, I obtained a total of 294,232 naïve cell sequences, 161,313 IgM memory cell 
sequences and 94,841 IgG memory cell sequences.  
I first analyzed the variable gene regions of each sequence for the presence of 
insertions and deletions that did not shift the reading frame. The frequency of non-frameshift 
insertions (1.8% and 1.9% for IgM memory and IgG memory, respectively; Figure 31A) and 
deletions (2.0% and 2.6%; Figure 31B) was similar in both memory cell subsets. The 
frequency of both insertions and deletions was reduced significantly in the naïve subset 
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when compared to either IgM or IgG 
memory subsets. This finding is 
consistent with previous data suggesting 
that non-frameshift insertions and 
deletions within the variable gene are 
associated with the somatic 
hypermutation process. (Goossens et 
al., 1998; Wilson et al., 1998a; Bemark 
and Neuberger, 2003)  
 
Biased variable gene use in sequences 
containing somatic hypermutation-
associated insertions and deletions.  
I next examined the sequences 
containing somatic hypermutation-
associated insertions and deletions 
(SHA indels) for evidence of biased 
variable gene use. The VH4 variable 
gene family was much more common in 
the population of sequences containing 
insertions (57%; Figure 31C) than in the 
total antibody repertoire (24%), while the 
 
Figure 31. Frequency and variable gene use of sequences containing non-frameshift insertions or 
deletions. The frequency of (A) insertions or (B) deletions that were codon-length (i.e., did not result in protein 
reading frame shift) was determined separately for the naïve, IgM memory and IgG memory subsets. The 
variable gene usage of VDJ gene recombinants containing insertions (C; white bars) or deletions (D; grey 
bars) was compared to the variable gene usage of the total repertoire (C and D; black bars).  
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VH1 and VH3 families were observed less frequently in the insertion population (7.6% and 
28%, respectively) than in the total repertoire (19% and 43%). In the population of 
sequences containing non-frameshift deletions, both VH3 and VH4 families (51% and 38%; 
Figure 31D) were more frequent than in the total repertoire (43% and 24%). The population 
of sequences with deletions also displayed reduced use of the VH1 family (4.8%) and VH5 
family (1.3%) compared to the total repertoire (19% and 6.8%, respectively). 
 
Antibody sequences containing SHA indels were highly mutated.  
Since SHA indels are only rarely induced by the somatic hypermutation process, I 
hypothesized that antibody sequences containing SHA indels would display evidence of 
increased affinity maturation. I examined sequences containing SHA indels from both IgM 
memory (Figure 32A) and IgG memory (Figure 32B) subsets for evidence of increased 
affinity maturation. The total IgM memory subset displayed a mean mutation frequency of 
12.6 mutations per sequence. Significantly higher mutation frequencies were seen in 
sequences from the IgM memory subset containing either SHA insertions (17.8; p = 0.0017) 
or SHA deletions (16.1; p = 0.0022). Sequences from the total IgG memory subset 
contained, on average, 14.9 mutations per antibody sequence. Much like the IgM memory 
subset, significantly higher mutation frequencies were seen in IgG memory sequences 
containing either SHA insertions (19.0; p = 0.0056) or SHA deletions (20.2; p = 0.0015). 
 
Duplication of flanking sequence was observed in most non-frameshift SHA insertions.  
For the population of sequences containing non-frameshift SHA insertions, the 
sequence immediately adjacent to the insertion (on either the 5ʹ′ or 3ʹ′ side of the insertion, 
hereafter referred to as the “flanking region”) was analyzed for homology to the sequence of 
the insertion. Since sequences containing insertions are highly mutated (Figure 32A-B), it is 
possible that additional mutations in the insertion sequence or the flanking region 
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accumulated following the insertion event. 
Therefore, flanking regions that identically 
matched the insertion sequence or flanking 
regions that contained a single mismatch 
were considered likely duplications. 
Although only 20% of insertion sequences 
identically matched flanking regions, 82% of 
sequences with insertions either identically 
matched or contained a single mismatch 
(Figure 32C), suggesting that sequence 
duplication was the primary mechanism of 
SHA insertions. 
 
Mutations and SHA indels are differentially 
localized in framework and complementarity 
determining regions.  
Although the somatic hypermutation 
process, which typically results in point 
mutations, and SHA indels have been 
shown to be linked, (Goossens et al., 1998; 
Figure 32. Sequences containing SHA indels are highly mutated. Sequences from the IgM memory 
(A) or IgG memory (B) subsets were segregated into three groups: the total sequence pool for each 
subset (total), sequences containing insertions, or sequences containing deletions. The mean number of 
mutations for each of these groups was calculated for each of four healthy donor sequence pools. (C) For 
each insertion, the 5ʹ′ flanking sequence was analyzed for identity to the insertion sequence. The fraction 
of sequences with insertions that contained flanking regions that were a perfect match to the insertion 
sequence (match) or those that contained less than two mismatches (≤1 Mismatch) are plotted for each of 
four healthy donors. (D) Mutations and SHA indels (Ins/Del) were each grouped by localization in either 
framework (FR) or complementarity determining region (CDR). ** = p<0.01 
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Wilson et al., 1998a; Bemark and Neuberger, 2003) it is unclear whether the location of SHA 
indels is driven primarily by frequency of somatic hypermutation, or whether there are 
additional structural constraints that apply to SHA indels, but not substitutions. The somatic 
hypermutation process is known to preferentially target complementarity determining 
regions (CDRs) over framework regions (FRs) for a variety of reasons, including the 
increased presence of genetically encoded mutation hotspots. I analyzed the position of 
mutations and SHA indels (Figure 32D) and observed a significant increase in the fraction of 
SHA indels found in FRs and a decrease in the fraction of SHA indels found in CDRs when 
compared to mutations. 16% of mutations were found in FRs, while 24% of observed SHA 
indels were found in FRs (p = 0.0075). Conversely, 85% of mutations were found in CDRs, 
while only 76% of SHA indels were found in CDRs (p = 0.0075). 
 
SHA indels revealed a hypervariable region 4 (HV4)-like region within FR3.  
Sequences containing non-frameshift SHA insertions or deletions were analyzed for 
the position of the insertion or deletion. Insertions and deletions were grouped by codon 
position, and the frequency of insertions (Figure 33A) or deletions (Figure 33B) at each 
codon position was determined. Non-frameshift insertions and deletions were both 
concentrated in CDRs and the portion of FRs in close proximity to CDRs. The most common 
codon position for insertions was codon 35, which is in CDR1. The most common codon 
position for deletions was codon 57, which is in CDR2. Surprisingly, there was a cluster of 
codons in FR3 (codons 81-87) that contained a high frequency of deletions. This cluster of 
deletions was located in the middle of framework region 3a (FR3a, codon positions 78-93), 
which corresponds to hypervariable region 4 (HV4, also sometimes referred to as CDR4) in 
T cell receptors. A less prominent cluster of insertions also was seen in a similar location in 
FR3a. 
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Figure 33. Genetic location and length distribution of non-frameshift insertions and deletions. The 
frequency of (A) insertions or (B) deletions at each codon of the variable gene reading frame was determined. 
The framework regions (FR) and complementarity determining regions (CDR) region were identified. The length 
distribution of insertions (C) or deletions (D) at each codon of the variable gene reading frame is shown. The 
mean value ± SEM for four donors is shown. (E) Comparison of the fraction of insertions (filled circles) or 
deletions (open circles) that were localized to each FR or CDR. The mean value ± SEM for four donors is shown. 
Comparison of the location of insertions (F) or deletions (G) for each FR or CDR is shown. The mean value ± 
SEM for four donors is shown. 
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 I next performed a comparative analysis of the relative frequency of insertions and 
deletions located in the sequences encoding the two CDRs and three FRs that constitute 
the heavy chain variable (VH) gene (Figure 33E). The fraction of insertions observed in 
CDR1 was significantly higher than the fraction of deletions (47% of insertions were found in 
CDR1 while 29% of deletions were found in CDR1; p = 0.008), with a similar pattern seen in  
FR2 (13% of insertions and 7% of deletions; p = 0.007). In contrast, the fraction of deletions 
found in CDR2 was significantly higher than the fraction of insertions (50% of deletions and 
26% of insertions; p = 0.006). There was no statistically distinguishable difference between 
the fraction of insertions and deletions in either FR1 or FR3. 
 
Similar localization of insertions and deletions.  
We again clustered non-frameshift insertions and deletions by codon position and 
calculated the mean insertion length (Figure 33C) for each codon position. As seen with 
insertion frequency, long insertions tended to concentrate in CDRs and in the portions of 
FRs that are immediately proximal to CDRs. An additional region containing a high 
concentration of long insertions and deletions was observed between codons 82 and 97 in 
FR3. Analysis of the mean insertion length of the three FRs (Figure 33F) revealed a trend 
toward longer insertions in FR3 when compared to FR1 (p = 0.13) and a significant increase 
in insertion length in FR3 when compared to FR2 (p < 0.01). Analysis of the mean insertion 
length of the two CDRs revealed a significant increase in insertion length in CDR2 when 
compared to CDR1. 
Analysis of deletion length at each codon position (Figure 33D) produced results that 
were similar to the insertion length distribution, with increased deletion lengths found in 
CDR1, CDR2 and FR3. A region between codons 82-97 contained extremely long deletion 
events, with codon 76 displaying a mean deletion length of 54 nucleotides and codon 78 
displaying a mean deletion length of 45 nucleotides. Interestingly, the location of the region 
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of long FR3 deletions corresponds to the location of increased FR3 deletion frequency. 
While the distribution of long insertions and deletions was largely similar in pattern, there 
was a short region between codons 51 and 55 in FR2 that contained very long deletions, 
and there was no corresponding region within FR2 for which long insertions were observed. 
Analysis of the mean deletion length of the three FRs (Figure 33G) revealed significantly 
longer deletions in FR2 and FR3 when compared to FR1 (p < 0.05). We also observed a 
small but significant increase in the deletion length in CDR1 when compared to CDR2. As 
with insertions, the CDR with lower alteration frequency (CDR2 for insertions, CDR1 for 
deletions) contained a significantly longer mean insertion or deletion length. 
 
Structural display of insertion and deletion frequency and length distribution revealed 
Figure 34. Structural location of non-frameshift insertions and deletions. A space-filling representation of 
the high resolution structure of the representative human Fab del2D1 determined by x-ray crystallography 
(citation) is shown at left. The del2D1 antibody light chain is colored dark grey.  The del2D1 antibody heavy chain 
CDR1 (green), CDR2 (magenta), CDR3 (orange) and FR3 (cyan) regions are indicated, with the remaining 
heavy chain regions colored light grey. The insertion and deletion frequency were determined for each codon 
position in the variable gene. In the middle two panels, the surface of del2D1 is colored to indicate insertion or 
deletion frequency. The mean insertion and deletion length were calculated for each codon position in the 
variable gene. In the right two panels, the surface of del2D1 is colored to indicate mean insertion or deletion 
length in nucleotides (nt). 
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regions of antibody structural plasticity.  
To gain a better understanding of 
the location of insertions and deletions in 
the context of a fully folded antibody 
protein, we mapped the frequency and 
length distribution of both insertions and 
deletions onto a space-filling model of a 
representative antibody (Figure 34). The 
model we used was derived from 
crystallographic structural data for the 
human  
influenza virus specific monoclonal 
antibody (mAb) 2D1 that we had isolated 
in our laboratory and previously reported 
(Krause et al., 2011). Insertion or deletion 
frequency was determined by calculating 
the log10 of the frequency for each codon 
position and represented as a 
blue_white_red gradient on the surface of 
the mAb 2D1 structure. Insertion and 
deletion frequency hotspots were observed 
at the top of the protein, with peak 
insertion and deletion frequencies 
appearing near the apex of the CDR1 and 
CDR2 loops. The side orientation revealed 
Figure 35. Difference in tolerance of long insertions 
and deletions in FRs and CDRs. (A) Non-frameshift 
insertions (black) or deletions (grey) were grouped by 
length and the frequency of each insertion or deletion 
length was calculated. The mean value ± SEM for four 
donors is shown. Non-frameshift insertions (B) or 
deletions (C) were grouped by length and the location of 
each insertion or deletion length to FRs (solid circles) or 
CDRs (open circles) was determined. The mean value ± 
SEM for four donors is shown.  
# = p<0.10, * = p<0.05, ** = p<0.01, *** = p<0.001 
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a reduced insertion and deletion 
frequency in the highly structured 
framework regions, with the lone 
framework hotspot occurring in a 
surface-exposed loop region of FR3.  
 Insertion and deletion length 
distribution was determined by 
calculating the log2 of the mean 
insertion length for each codon position 
and represented as a blue_white_red 
gradient on the surface of the mAb 2D1 
structure. The longest insertions and 
deletions were focused in FR3, and 
were isolated to loop and short alpha-
helical regions. 
 
Long deletions were less frequent than long insertions and were tolerated poorly in CDRs.  
I examined the ability of the antibody repertoire to generate and maintain sequences 
with long insertions and deletions. Insertions and deletions were both grouped by length (in 
nucleotides) and selected lengths for which we had at least 100 representative sequences 
with that length of insertion or deletion. The frequency of insertions and deletions was 
plotted for each length (Figure 35A), which revealed a significantly higher frequency of long 
insertions when compared to frequency of long deletions.  
I next investigated whether or not there was a structural reason for the greater 
tolerance of long insertions over long deletions. Insertions and deletions were again grouped 
by length (in nucleotides) and plotted the frequency of insertions (Figure 35B) or deletions 
Figure 36. SHA indel frequency in HIV-infected and 
HIV-uninfected individuals. Sequences from HIV-
infected donors (black bars; n=4) contained a higher 
frequency of insertions (A) or deletions (B) than HIV-
uninfected healthy donors (white bars; n=4). 
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(Figure 35C) by location in either FR or CDR. We found that both long and short insertions 
were concentrated in CDRs, with less than 30% of the longest insertion events occurring in 
FRs. In contrast, however, long deletions were highly concentrated in FRs, with 89% of the 
longest deletions occurring in FRs. This strong preference against long deletions in CDRs is 
likely due to the limited length of the CDR loops. Most CDR1 and CDR2 loops are only 8-9 
amino acids long, which likely restricted the ability of these CDR loops to structurally 
accommodate long deletions. 
 
SHA indels are more frequent in HIV-infected individuals 
 Since many bnAbs contain SHA indels, the peripheral blood antibody repertoires of 
four HIV-infected individuals were examined for the frequency of SHA indels and compared 
with the repertoires of HIV-uninfected individuals. There was a consistent increase in the 
frequency of SHA insertions of all lengths in HIV-infected individuals compared to HIV-
uninfected individuals (Figure 36A; p=0.0007). There was also an increase in the frequency 
of SHA deletions across the spectrum of SHA deletions lengths in HIV-infected individuals 
compared to HIV-uninfected individuals (Figure 36B; p=0.0044). 
 
Discussion 
 Broadly neutralizing antibodies against HIV are rarely found and often contain 
genetic or structural features that are unique or infrequently observed. SHA indels and 
exceptionally long HCDR3s, while uncommon in the normal circulating antibody repertoire, 
are frequently found in broadly neutralizing HIV antibodies. Much effort is currently being 
expended on the design of potential vaccine strategies that effectively elicit a broadly 
neutralizing anti-HIV antibody response. It is unclear, however, whether the designed 
immunogens should be constructed to induce the unique genetic features found in HIV 
antibodies, or whether the presence of such unique genetic features in the antibody 
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repertoire of uninfected individuals would enable selection of pre-existing antibodies with the 
required genetic features by an appropriately designed immunogen. The data presented in 
this chapter indicates that two frequently observed genetic features of HIV antibodies, SHA 
indels and exceptionally long HCDR3s, are found in the antibody repertoires of HIV-
uninfected individuals. 
 
Comparison of long HCDR3s in the HIV-infected and HIV-uninfected repertoire 
 Although designing a strategy for selecting or inducing antibodies with long HCDR3s 
might be a groundbreaking step for vaccine design, very little is known about the genetic 
origin of such antibodies. Two general models have been proposed for the generation of 
antibodies with long HCDR3s. First, it is possible that long HCDR3s are generated through 
the introduction of multiple short insertion events during the somatic hypermutation process 
(Wilson et al., 1998a; Reason and Zhou, 2006). Indeed, we have shown recently that a 
genetic insertion was a critical feature that mediated affinity maturation and acquisition of 
neutralizing potency for a human antibody that inhibits influenza virus (Krause et al., 2011), 
although this was a short insertion that did not cause a long HCDR3. Alternatively, it is 
possible that long HCDR3s could be created at the time of recombination through a 
combination of extensive incorporation of non-templated nucleotides during N- and P-
addition and the selective use of longer germline gene segments. In this setting, the 
extended length of the HCDR3 would be established without the need for the affinity 
maturation process. In this study, I found that antibodies containing long HCDR3s are 
created primarily at recombination and not through affinity maturation. In addition, several 
genetic features were identified that are frequently seen in antibodies with long HCDR3s but 
are uncommon in the rest of the antibody repertoire. Finally, analysis of long HCDR3 
encoding antibody sequences from HIV-infected donors produced results that closely 
mirrored those from healthy donors. These results suggested that antibodies with long 
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HCDR3s in HIV-infected individuals also typically were generated at the time of 
recombination. 
These data show that increased HCDR3 length did not correlate with either 
increased mutation count or insertion frequency in the peripheral blood antibody population, 
although mutation count and insertion frequency were themselves strongly correlated. 
Further, these studies demonstrated the presence of B cells with receptors incorporating 
long HCDR3s in the naïve cell population. In fact, the naïve B cell subset contained a higher 
proportion of long HCDR3s than did the affinity-matured memory B cell population, 
suggesting that long HCDR3s are produced independent of the affinity maturation process. 
Together, the lack of correlation between increased HCDR3 length and increased number of 
insertions arising during affinity maturation and the presence of a sizeable fraction of long 
HCDR3s in the memory cell population strongly indicate that long HCDR3s are not primarily 
generated by repeated rounds of affinity maturation. 
I also examined several events that occur during the recombination process and 
discovered many correlations between these molecular features of recombination and 
increased HCDR3 length. First, an increased number of nucleotides introduced by N- or P-
addition were both found to be correlated with increased HCDR3 length. Next, germline 
diversity genes in the D2/D3 family and the germline joining gene JH6 were found to be 
highly favored in long HCDR3s. In fact, over half of all of the longest HCDR3s used both of 
these germline sequence elements, while fewer than 5% of the shortest HCDR3s contained 
both sequence elements. Finally, somewhat surprisingly, RF2 was highly preferred in long 
HCDR3s. Previous work by several groups has indicated that long, hydrophobic HCDR3s 
often possess autoreactive properties (Crouzier et al., 1995; Aguilera et al., 2001; 
Wardemann et al., 2003; Haynes et al., 2005), so it seems likely that RF2 is used 
preferentially primarily because of the reduced hydrophobicity profile compared to other 
reading frames. 
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The observation that long HCDR3s are composed of conserved sequence elements 
is of critical importance for two reasons. First, these findings provide information that might 
be used in the design of strategies to selectively induce expansion of particular B cells 
encoding antibodies with long HCDR3s. Since long HCDR3s are generated using a limited 
set of germline gene segments, and since those germline segments are rarely used in short 
HCDR3s, immunogens designed to target these conserved sequence elements might 
induce an antibody response that is enriched in antibodies containing long HCDR3s. 
Second, knowledge of conserved genetic elements present in the majority of long HCDR3s 
provides a starting point for affinity maturation of these antibodies. For example, it has been 
suggested that one route to development of an HIV vaccine would be to identify structures 
of neutralizing epitopes and design immunogens that mimic these epitopes, with the goal of 
eliciting an antibody response focused on the desired neutralizing epitope (Burton, 2002; 
Douek et al., 2006; Burton, 2010; Walker and Burton, 2010). An alternative to this approach 
has been proposed, however, which consists of identifying the structural and genetic 
components of potently neutralizing antibodies and designing immunogens that gradually 
and specifically induce desired affinity maturation events that result production of broadly 
neutralizing antibodies. In effect, this alternative process would involve rationally guiding the 
affinity maturation process through the selective use of sequential immunizations (Pancera 
et al., 2010). This strategy would require detailed knowledge not only of the desired final 
product, in this case a PG9- or PG16-like broadly neutralizing antibody, but also of the 
genetic characteristics of the naïve predecessors of the desired broadly neutralizing 
antibody. The work presented here provides a substantial step toward realization of this 
alternative method of vaccine development. Until this study, little was known about the 
process of generating antibodies with long HCDR3s or the genetic characteristics of the 
naïve predecessors of such antibodies. I have identified conserved genetic elements in the 
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long HCDR3 antibody population that form a potential starting point from which rationally 
guided affinity maturation may begin. 
In the case of mAbs PG9 and PG16, this potential is especially enticing. Since many 
of the residues in these mAbs that are critical for binding and neutralization are encoded in 
the germline gene sequence, little affinity maturation may be necessary to produce a 
potently neutralizing antibody. In fact, all but two residues identified in PG9 and PG16 as 
critical to binding and neutralization were present in the germline D3-3 or JH6 genes, and 
those additional critical residues were generated by random N-addition. Accordingly, I 
suggest that it is highly likely that there are naïve antibodies in HIV-unexposed individuals 
that use D2/3 and J6 gene segments and by random happenstance of N-addition, encode 
many of the residues critical to PG-like neutralization. Thus, while germline reversions of 
PG9 and PG16 are non-neutralizing (Pancera et al., 2010), it is possible that the naive 
predecessors of PG-like antibodies will require only limited affinity maturation to gain 
neutralization capacity. If this is the case, efforts should be focused on selective induction of 
these rare antibodies containing long HCDR3s, rather than sequential immunization 
strategies to “build up” long HCDR3s with somatic insertions. 
 
SHA indels in the HIV-uninfected repertoire 
 Many of the most broad and potently neutralizing HIV antibodies contain SHA indels 
that are critical for neutralization. However, B cells encoding antibodies with SHA indels are 
unusual in the peripheral circulation, with less than 2% of antibody sequences containing 
such insertion or deletion events. Due to their rarity, a comprehensive analysis of SHA 
indels has been difficult in the past. High throughput sequencing was used to determine the 
location and length distribution of SHA indels; for the most part, the location of SHA indels 
was similar to that of conventional somatic mutations. However, substantial differences in 
SHA indel location were identified that were likely related to structural constraints that apply 
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to SHA indels but do not apply to substitutions. This analysis analyses revealed regions of 
antibody structural plasticity, i.e., regions that were able to accommodate addition or 
subtraction of sequence without compromising structural integrity.  
With much effort being directed toward rational design of both antigens(Correia et al., 
2010; Ofek et al., 2010; Wu et al., 2010a; Azoitei et al., 2011) and antibodies,(Diskin et al., 
2011) it is critical to understand the regions of the antibody molecule that can withstand 
extensive alteration while maintaining the desired structural conformation. The broadly 
neutralizing HIV antibody PGT128 is exceptionally potent, and the neutralization potency 
requires the presence of a six amino acid deletion in HCDR2. The inducement of such a 
large deletion through vaccination is thought to be very difficult, however, this work has 
identified the frequency of such deletions in the HIV-uninfected repertoire. Although such 
deletions are rare, they are present, which raises the possibility of rationally designed 
vaccine designed to perform the presumably simpler task of selection of antibodies 
containing the required genetic features, rather than elicitation. 
Interestingly, SHA indels were more frequently observed in HIV-infected individuals 
than in HIV-uninfected individuals. While it is possible that HIV infection specifically selects 
for and enhances the frequency of antibodies containing SHA indels, it is also possible that 
the increase in SHA indels is a side effect of chronic infection and is not specific to HIV. 
Chronic infections involve repeated exposure to antigen and likely result in repeated 
stimulation of the same clones of antigen-specific B cells. Since SHA indels are associated 
with the somatic hypermutation process, it is possible that the increase in SHA indels seen 
in HIV-infected donors was simply an artifact of repeated stimulation of a small number of 
HIV-specific B cell clones. To discriminate any HIV-specific effect from effects that are 
generally caused by chronic infection, further analysis of the antibody repertoires of 
individuals with chronic infections other than HIV (Hepatitis C, for example) must be 
performed.
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CHAPTER V 
 
STRUCTURAL HOMOLOGS OF THE BROADLY NEUTRALIZING HIV ANTIBODY PG9 
IDENTIFIED IN THE PERIPHERAL BLOOD OF UNINFECTED INDIVIDUALS 
 
Introduction 
 
The clonally-related broadly 
neutralizing antibodies PG9 and PG16 
contain extremely long HCDR3s with 
which they are able to penetrate the 
glycan shield on gp120 and interact 
directly with the gp120 protein (Figure 
37). Both antibodies target a conserved 
epitope on the V1/V2 and V3 loops and 
interact directly with carbohydrates on 
the surface of gp120 (McLellan et al., 
2011). Serum antibodies targeting 
glycan-dependent epitopes were found 
in approximately half of the tested 
individuals with broadly neutralizing 
activity, and depletion of these 
antibodies resulted in loss of 
neutralization potency (Gray et al., 
Figure 37. Crystal structure of PG9 in complex with 
Cap45 V1/V2 scaffold protein. The crystal structure of 
PG9 (heavy chain in blue, light chain in yellow) in 
complex with the CAP45 V1/V2 scaffold protein 
revealed the binding mode of PG9. The extremely long 
HCDR3 loop is able to reach past glycans at positions 
N156 and N160 (light purple) to contact the CAP V1/V2 
protein (purple). Although most of the gp120 protein 
has been replaced by the 1FD6 scaffold (light grey), the 
V1/V2 loop region is in a position consistent with the 
virion particle located at the top of the page. While the 
HCDR3 reaches past glycans to interact directly with 
conserved regions of the polyprotein, light chain CDRs 
make direct contact with the glycan at position N160. 
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2009; Walker et al., 2010). PG9 and 
PG16 are able to more potently 
neutralize older virus isolates (isolated 
between 1985-1989) than VRC01, 
which targets the CD4bs, and 
contemporary virus isolates (2003-
2006) are more resistant to 
neutralization by VRC01 than to 
neutralization by PG9 and PG16 
(Euler et al., 2011). In addition to the 
exceptional length of the HCDR3, the 
loop contains unique secondary 
structural elements that are mediated 
by a complex hydrogen-bonding 
network. This secondary structure, 
referred to by some as an “ax-head” or 
“hammer-head” structure, is critical to 
the binding interaction and appears to be stable in both the antigen bound state and in the 
unbound state (Pancera et al., 2010; McLellan et al., 2011).  
Antibodies containing long HCDR3s have previously been shown to be present in the 
peripheral blood repertoire of HIV-uninfected individuals (Briney et al., 2012a). However, 
neutralization by PG9 and PG16 depends not only on the presence of a long HCDR3, but 
also on the unique secondary structure within the HCDR3 loop. In collaboration with my 
computational colleague, Jordan Willis, I examined the peripheral blood repertoire to identify 
the presence of antibodies that contain structural homology to the unique HCDR3s of PG9 
and PG16. 
Figure 38. Most healthy donor HCDR3s are not 
predicted to accommodate a PG9-like structure. The 
RMSD and Rosetta Energy Score was plotted for each 
decoy of PG9 (blue), PG16 (red) and each healthy 
donor antibody sequence with a 30 amino acid long 
HCDR3 (black).  
	  	   98 
 
Results 
 
The majority of 30 amino acid HCDR3s are not structural homologs of PG9 or PG16 
 Using ultra-high throughput HCDR3 sequencing, I isolated approximately 5.5 million 
unique HCDR3s from four individuals. The HCDR3 repertoire was examined for the 
presence of HCDR3s with a length of 30 amino acids, and 2200 were identified. Each 
HCDR3 was then threaded by Jordan onto a crystal structure of PG9 bound to a V1/V2 
epitope scaffold by Jordan using the Rosetta software suite. To avoid capture of any 
particular modeling run in a local energy minimum as opposed to a global minimum, each 
sequence was threaded multiple times. Each individual run of a single sequence is referred 
to as a decoy (as in, multiple decoys were run for each sequence). Each decoy was given a 
Figure 39. Long HCDR3s from HIV-uninfected donors are predicted to adopt a PG-like structure. 
Rosetta Energy Score and RMSD of (A) the top-scoring 10% of decoys or (B) all decoys of the single top 
scoring antibody sequence. 
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Rosetta Energy Score (RES), 
which is similar to change in 
Gibbs’ Free Energy in that a lower 
score indicates an energetically 
favorable conformation. In addition 
to threading HCDR3 sequences 
from HIV-uninfected donors, 
Jordan also threaded the HCDR3s 
of PG9 and PG16. These positive 
controls allowed the definition of a 
threshold RES for which adoption 
of the PG9 conformation was 
likely. Based on the RES and root mean square deviation (RMSD, a measure of the spatial 
similarity of the final predicted structure to the PG9 crystal structure), the overwhelming 
majority of HIV-uninfected HCDR3s are predicted to be unable to conform to the PG9 
HCDR3 structure (Figure 38).  
 
Several HCDR3s from HIV-uninfected individuals are predicted to conform to the PG9 
crystal structure 
 Limiting the plot of antibody decoys to just the to lowest scoring 10% of sequences 
revealed several sequences that several sequences approach the RES and RMSD values 
of PG9 and PG16 (Figure 39A). In fact, the best scoring sequence (the lowest average 
RES) has RES scores that are comparable to PG9 and PG16, although the RMSD is slightly 
higher (Figure 39B). While there is little homology between the HCDR3 sequence of the top 
scoring sequence and the HCDR3 sequence of PG9 or PG16, but the predicted structure of 
the antibody is very similar to that of PG16 (Figure 40).  
Figure 40. Structural homology between PG16 and naïve 
B cell sequences isolated from HIV-uninfected donors. 
The PG16 crystal structure, threading of the PG16 sequence 
onto the PG16 crystal structure (remodel) and the top 
scoring naïve sequence (Top Naïve) are shown. Each 
structure is colored according to the Rosetta Energy Score, 
with green indicating favorable RES and red indicating 
unfavorable RES. 
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The three best scoring HCDR3 sequences from HIV-uninfected individuals were 
used to generate chimeric antibody sequences in which the HCDR3 of PG16 was replaced 
the HCDR3 sequence from the HIV-uninfected individual. Of the three chimeric antibodies 
that were created, two appeared to contain somatically related HCDR3s and were unable to 
be expressed. The third sequence was expressed as a full-length IgG1 molecule paired with 
the PG16 light chain, but was not able to bind any of a panel of HIV isolates. This was not 
unexpected, however, since the homology of the healthy donor HCDR3 with PG16 HCDR3 
extended only to the secondary structure of the HCDR3 loop, not to the individual amino 
acid side chains. 
 
Discussion 
 
 In close collaboration with Jordan Willis, who performed all of the computation 
detailed in this chapter, I have discovered the presence of antibodies in the HIV-uninfected 
peripheral blood antibody repertoire that are predicted to be highly structurally homologous 
to the unique HCDR3 structure of the broadly neutralizing antibodies PG9 and PG16. Not 
only were these antibodies identified in the HIV-infected donors, but they were identified in 
the naïve B cell population, indicating that no somatic mutation is necessary to produce 
antibodies with predicted structural similarity to PG9 and PG16. Not only does this discovery 
provide useful information about the genetic origin and development of broadly neutralizing 
HIV antibodies, it also raises the possibility of a novel method of vaccine development. Most 
currently available vaccines are based on some form of viral mimicry, whether through the 
use of inactivated or attenuated virus, through the use of viral subunits, or through the use of 
scaffolded viral epitopes. Various forms of HIV viral mimicry have been tested, and each 
effort has been unsuccessful at generating potently neutralizing antibodies and protection 
from infection. Detailed knowledge of the HIV-uninfected repertoire and identification of 
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potential bnAb precursors in the HIV-uninfected repertoire may allow an alternate method of 
vaccine development in which immunogens are designed to target bnAb precursors and 
guide them toward the desired neutralizing antibody. While it is possible that the 
immunogens designed to target bnAb precursors may mimic the virus in some form, it is 
also possible, even likely, that immunogens designed to rationally direct the affinity 
maturation process have little homology to the original pathogen.  
One could envision a multi-step vaccination procedure in which a panel of 
immunogens is introduced in sequence, with each immunogen designed to elicit a handful of 
somatic mutations in the progenitor antibody sequence. Each stage of the vaccination 
process would produce intermediate antibodies that become closer to the desired bnAb 
response with continued vaccination. Intriguingly, since less somatically mutated progenitors 
of bnAbs have been shown to be less broadly neutralizing than the bnAb itself (Wu et al., 
2011), it is possible that the partially affinity matured intermediate antibodies that are elicited 
by the multi-step vaccination procedure may provide partial protection from infection even 
before the entire vaccination regimen is complete. 
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CHAPTER VI 
 
DISCUSSION 
 
Since the start of the HIV/AIDS outbreak over two decades ago, intense energy and 
extraordinary resources have ben invested in the search for a protective vaccine. All early 
attempts were either ineffective or, in the worst case, enhanced the possibility of infection. 
Recently, the RV144 trial in Thailand was modestly successful, but large gains in 
effectiveness must be made before a vaccine is suitable for widespread distribution.  
The tremendous global success with other viral vaccines raises the question as to 
why HIV vaccine development has been so difficult. Many of the difficulties lie in distinct 
properties of this virus compared with other viruses. Foremost among these is HIV’s 
enormous sequence diversity. Because of an error-prone reverse transcriptase, a high 
propensity for recombination, and an extremely rapid turnover in vivo, HIV’s capacity for 
mutation and adaptation is enormous (Korber et al., 2001). Viruses even within the same 
clade may differ by up to 20%, and in places such as Africa where there are multiple 
prominent clades, circulating viruses can differ within the highly variable envelope protein by 
up to 38% (Korber et al., 2001; Walker and Korber, 2001). Indeed, the amount of HIV 
diversity within a single infected individual can exceed the variability generated over the 
course of a global influenza epidemic, the latter of which results in the need for a new 
vaccine each year. With more than 33 million people currently infected with HIV, and the 
need for a vaccine that simultaneously protects against all potential exposures, HIV 
sequence diversity alone represents a staggering challenge. 
A further hurdle to HIV vaccine development is that HIV is an infection of the immune 
system, specifically targeting CD4+ T lymphocytes. Within days of exposure, massive 
infection and loss of memory CD4+ T cells ensues, particularly within the gut-associated 
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lymphoid tissue (Brenchley et al., 2004; Mehandru et al., 2004) where most of these cells 
reside. The loss of these cells, which are critical for coordinating effective immune 
responses, results in considerable immune impairment within the first weeks of HIV 
infection. Further, bacterial translocation across a damaged intestinal mucosa may even 
help to drive ongoing CD4+ T cell activation and facilitate viral replication, which is most 
efficient in activated cells (Brenchley et al., 2006). 
Yet another challenge is that HIV has evolved strategies to avoid immune 
elimination. HIV rapidly establishes a latent reservoir of infected lymphocytes by integration 
of its genetic material into the host chromosome. This represents an enormous obstacle 
because this is an irreversible process that occurs immediately after infection and ends only 
with the death of the infected cell (Chun et al., 1997). The virus is immunologically silent in 
this latent reservoir, but production of infectious virus particles may be subsequently initiated 
if cells become activated at a later time. The stability of this reservoir means that lifelong 
infection of the host is maintained, even in the face of potent anti-HIV medication. 
One potentially promising avenue of immunogen design is to produce epitope mimics 
determined from structural studies of antibody-antigen interactions. In the case of many of 
the most broad and potently neutralizing HIV antibodies, however, unique genetic or 
structural features are present that may be difficult to elicit through vaccination. An easier 
path may involve selection of antibodies in the HIV-uninfected antibody repertoire that 
already contain the desired unique elements. In this case, the immunogens may be 
designed not to mimic the epitope, but to select likely progenitors to the bnAb. Thus, the 
immunogen may be potentially designed even in cases where the crystal structure of the 
antibody-antigen complex is difficult or impossible to obtain. The first step toward 
determining the potential of this vaccine strategy, however, is to evaluate whether antibodies 
containing the desired unique features of HIV bnAbs exist within the HIV-uninfected 
antibody repertoire. In this report, I focused on the identification of three unique elements 
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that are commonly found in HIV bnAbs: long HCDR3s, SHA indels and unique secondary 
structure within the HCDR3 loop.  
Long HCDR3s were identified in the HIV-uninfected human repertoire and were 
found to utilize a select subset of germline genes. These same germline genes contain 
many of the critical residues for binding and neutralization by the broadly neutralizing 
antibodies PG9 and PG16. This indicates not only that potential precursors to PG9 and 
PG16 are present in the HIV-uninfected repertoire, but that the majority of long HCDR3s in 
the HIV-uninfected repertoire are built with the same genetic building blocks as PG9 and 
PG16. SHA indels had previously been identified in the healthy donor peripheral blood 
repertoire, but I analyzed the position and length distribution of SHA indels on a much larger 
sequence set. As SHA indels are infrequent, study of the distribution of these events has 
been difficult. When attempting to identify the frequency of a particular SHA indel found in a 
bnAb, knowledge of the approximate frequency of all SHA indels in the healthy donor 
repertoire, as was known before this report, is insufficient. To accurately identify the 
potential precursor frequency of the bnAb of interest, the frequency of sequences containing 
the appropriate length SHA indel at the appropriate codon position is necessary. In the 
course of this study, I have assembled a comprehensive database of the position and 
location of SHA indels in the healthy donor peripheral blood repertoire. Finally, we analyzed 
the HIV-uninfected antibody repertoire for the presence of sequences that display predicted 
structural homology to the unique HCDR3 of PG9 and PG16. We isolated a handful of 
sequences with such predicted structural homology, although these sequences contained 
few of the required residues for proper interaction with HIV. Nevertheless, the presence of 
structural homologs to PG9 and PG16 suggests the possibility that an immunogen can be 
designed to select antibodies based on this structural homology and induce a relatively 
small set of somatic mutations in order to gain binding and neutralization capacity. 
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METHODS 
 
Sample Preparation and Sorting 
Peripheral blood was obtained from healthy adult donors following informed consent, under 
a protocol approved by the Vanderbilt Institutional Review Board. Mononuclear cells from 
the blood of four donors were isolated by density gradient centrifugation with Histopaque 
1077 (Sigma). Prior to staining, B cells were enriched by paramagnetic separation using 
microbeads conjugated with antibodies to CD19 (Miltenyi Biotec). Cells from particular B cell 
subsets were sorted as separate populations on a high speed sorting cytometer (FACSAria 
III; Becton Dickinson) using the following phenotypic markers, naïve B cells: CD19+/CD27-
/IgM+/IgG-/CD14-/CD3-, IgM memory B cells: CD19+/CD27+/IgM+/IgG-/CD14-/CD3- and IgG 
memory B cells: CD19+/CD27+/IgM-/IgG+/CD14-/CD3-. Total RNA was isolated from each 
sorted cell subset using a commercial RNA extraction kit (RNeasy; Qiagen) and stored at -
80°C until analysis. 
 
Tissue-specific total RNA and mRNA 
Purified polyA+ mRNA (lymph node) or total tissue RNA (all other samples) from the tissues 
of healthy human subjects was obtained from a commercial source (Clontech). 
 
cDNA synthesis and PCR amplication of antibody genes 
RT-PCR primers were originally described by the BIOMED-2 consortium (van Dongen et al., 
2003) and were slightly modified to suit amplification for large-scale parallel pyrosequencing 
(454 Sequencing; 454 Life Sciences/Roche). 100 ng of each total RNA sample and 10 pmol 
of each RT-PCR primer were used in duplicate 50 µl RT-PCR reactions using the OneStep 
RT-PCR system (Qiagen). Thermal cycling was performed in a BioRad DNA Engine PTC-
0200 thermal cycler using the following protocol: 50°C for 30:00, 95°C for 15:00, 35 cycles 
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of (94°C for 0:45, 58°C for 0:45, 72°C for 2:00), 72°C for 10:00. cDNA synthesis and 
amplification were verified by agarose gel electrophoresis before duplicate RT-PCR 
reactions were pooled. 5 µl of each pooled RT-PCR reaction was used as template for 100 
µl 454-adapter PCR reactions, which were carried out in quadruplicate. 20 pmol of each 
454-adapter primer and 0.25 units of AmpliTaq Gold polymerase (Applied Biosystems) were 
used for each reaction. Thermal cycling was performed in a BioRad DNA Engine PTC-0200 
thermal cycler using the following protocol: 95°C for 10:00, 10 cycles of (95°C for 0:30, 58°C 
for 0:45, 72°C for 2:00), 72°C for 10:00. Amplification was verified by agarose gel 
electrophoresis before quadruplicate 454-adapter PCR reactions were pooled. 
 
Amplicon Purification and Quantification 
Amplicons were purified from the pooled 454-adapter PCR reactions using the Agencourt 
AMPure XP system (Beckman Coulter Genomics). Purified amplicons were quantified using 
a Qubit fluorometer (Invitrogen). 
 
Amplicon Nucleotide Sequence Analysis 
Quality control of the amplicon libraries and emulsion-based clonal amplification and 
sequencing on the 454 Genome Sequencer FLX Titanium system were performed by the W. 
M. Keck Center for Comparative and Functional Genomics at the University of Illinois at 
Urbana-Champaign, according to the manufacturer’s instructions (454 Life Sciences). Signal 
processing and base calling were performed using the bundled 454 Data Analysis Software 
version 2.5.3 for amplicons. 
 
Antibody Sequence Analysis 
For germline gene assignments and initial analysis, the FASTA files resulting from 454 
sequencing were submitted to the IMGT HighV-Quest webserver (IMGT, the international 
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ImMunoGeneTics information system; www.imgt.org; founder and director: Marie-Paule 
LeFranc, Montpellier, France). Antibody sequences returned from IMGT were considered to 
be “high-quality” sequences if they met the following requirements: sequence length of at 
least 300 nt; identified variable and joining genes; an intact, in-frame recombination; and 
absence of stop codons or ambiguous nucleotide calls within the reading frame. 
 
Clustering of Antibody Repertoires 
We perform agglomerative hierarchical clustering with complete linkage on both VDJ genes 
and individual donor subsets. First, we perform a filter that removes VDJ genes with low 
counts of low variation across all samples. Then we calculate pairwise distances between 
genes and samples using Pearson correlation. We standardize the values in the heat map 
to display in the range -3 to +3. Dendrograms and heatmaps were created with Matlab 
R2010b. 
 
Analysis of Differential Expression of V(D)J Recombinants 
We use the edgeR software (Robinson et al., 2010) to calculate differential expression 
between tissues. EdgeR uses the negative binomial as the appropriate distribution for count 
data. We obtain dispersion estimates and test differential expression using the generalized 
linear model (GLM) likelihood ratio test. The columns in the table show the fold change 
between tissues and the p-value and Benjamini and Hochberg false discovery rate. 
 
Stringent Filtering for Putative V(DD)J recombinations 
The antibody sequence region identified by IMGT as a putative diversity gene is designated 
here as the “match region”. The length of the match region, minus any mismatches between 
the match region and the germline diversity gene, is designated the “match score”. Our 
filtering process required the match regions to contain a maximum of one nucleotide 
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difference from the germline diversity gene segment. The match score, which represents the 
number of identically matched nucleotides between the match region and the germline 
diversity gene segment, was required to be at least 60% of the overall length of the germline 
diversity gene segment, except in the case of the short IGHD7-27 gene segment for which 
we required a match score of 72% of the germline diversity gene length. 
 
Data Analysis 
All statistical analyses were performed with Graphpad Prism software. Three-dimensional 
antibody structural models were colored using MacPyMol and custom scripts. All Circos 
plots were made using Circos software (www.circos.ca/software). 
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